0001140361-20-024702 | 10-Q | XBRL Viewer

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2020	Nov. 05, 2020
Cover page.
Entity Registrant Name	Chembio Diagnostics, Inc.
Entity Central Index Key	0001092662
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		20,176,131
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-30379
Entity Tax Identification Number	88-0425691
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	555 Wireless Blvd.
Entity Address, City or Town	Hauppauge
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11788
City Area Code	631
Local Phone Number	924-1135
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	CEMI
Security Exchange Name	NASDAQ

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 28,687,453	$ 18,271,352
Accounts receivable, net of allowance for doubtful accounts of $276,210 and $62,000 as of September 30, 2020 and December 31, 2019, respectively	3,522,498	3,661,325
Inventories, net	12,363,486	9,598,030
Prepaid expenses and other current assets	1,007,473	693,013
TOTAL CURRENT ASSETS	45,580,910	32,223,720
FIXED ASSETS:
Property, plant and equipment, net	8,033,112	5,933,569
Finance lease right-of-use asset, net	248,892	210,350
OTHER ASSETS:
Operating lease right-of-use assets, net	6,316,221	7,030,744
Intangible assets, net	3,648,495	3,914,352
Goodwill	5,696,679	5,872,690
Deposits and other assets	462,664	543,539
TOTAL ASSETS	69,986,973	55,728,964
CURRENT LIABILITIES:
Accounts payable and accrued liabilities	6,558,782	5,526,243
Deferred revenue	3,865,754	125,000
Finance lease liabilities	57,715	41,894
Operating lease liabilities	710,535	568,294
Note payable	0	180,249
TOTAL CURRENT LIABILITIES	11,192,786	6,441,680
OTHER LIABILITIES:
Long-term operating lease liabilities	6,448,515	6,969,603
Long-term finance lease liabilities	200,397	171,953
Long-term debt, less current portion, net	18,040,427	17,644,149
Deferred tax liability	165,326	466,326
TOTAL LIABILITIES	36,047,451	31,693,711
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Preferred stock - 10,000,000 shares authorized; none outstanding	0	0
Common stock - $0.01 par value; 100,000,000 shares authorized; 20,213,956 shares and 17,733,617 shares issued at September 30, 2020 and December 31, 2019, respectively	202,139	177,335
Additional paid-in capital	124,622,252	95,433,077
Accumulated deficit	(89,967,147)	(71,585,003)
Treasury stock - 33,290 and 0 shares at cost, at September 30, 2020 and December 31, 2019, respectively	(150,919)	0
Accumulated other comprehensive (loss) income	(766,803)	9,844
TOTAL STOCKHOLDERS' EQUITY	33,939,522	24,035,253
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 69,986,973	$ 55,728,964

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
REVENUES:
TOTAL REVENUES	$ 10,272,478	$ 9,720,939	$ 22,243,234	$ 27,613,291
COSTS AND EXPENSES:
Cost of product sales	7,467,746	6,649,114	17,512,925	18,112,676
Research and development expenses	2,351,880	2,223,939	6,233,040	6,542,591
Selling, general and administrative expenses	5,348,958	4,455,588	13,903,192	12,565,601
Severance, restructuring and other related costs	11,651	0	1,122,310	0
Acquisition costs	0	0	63,497	395,612
TOTAL COSTS AND EXPENSES	15,180,235	13,328,641	38,834,964	37,616,480
LOSS FROM OPERATIONS	(4,907,757)	(3,607,702)	(16,591,730)	(10,003,189)
OTHER INCOME:
Interest expense, net	(735,819)	(195,970)	(2,110,011)	(183,368)
LOSS BEFORE INCOME TAXES	(5,643,576)	(3,803,672)	(18,701,741)	(10,186,557)
Income tax benefit	104,778	20,667	319,597	400,339
NET LOSS	$ (5,538,798)	$ (3,783,005)	$ (18,382,144)	$ (9,786,218)
Basic loss per share (in dollars per share)	$ (0.28)	$ (0.22)	$ (0.98)	$ (0.58)
Diluted loss per share (in dollars per share)	$ (0.28)	$ (0.22)	$ (0.98)	$ (0.58)
Weighted average number of shares outstanding, basic (in shares)	20,104,547	16,923,695	18,728,372	16,912,583
Weighted average number of shares outstanding, diluted (in shares)	20,104,547	16,923,695	18,728,372	16,912,583
Net Product Sales [Member]
REVENUES:
TOTAL REVENUES	$ 8,406,457	$ 8,510,629	$ 17,914,623	$ 23,381,906
R&D and Grant Revenue [Member]
REVENUES:
TOTAL REVENUES	1,654,500	971,980	3,756,161	3,528,033
License and Royalty Revenue [Member]
REVENUES:
TOTAL REVENUES	$ 211,521	$ 238,330	$ 572,450	$ 703,352

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in-Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Associated Other Comprehensive Income [Member]	Total
Balance at Dec. 31, 2018	$ 171,664	$ 90,953,788		$ (57,909,874)	$ 112,196	$ 33,327,774
Balance (in shares) at Dec. 31, 2018	17,166,459
Common Stock:
Restricted stock compensation, net	$ 0	281,248		0	0	281,248
Restricted stock compensation, net (in shares)	0
Options:
Stock option compensation	$ 0	66,259		0	0	66,259
Comprehensive income (loss)	0	0		0	202,186	202,186
Net loss	0	0		(2,816,533)	0	(2,816,533)
Balance at Mar. 31, 2019	$ 171,664	91,301,295		(60,726,407)	314,382	31,060,934
Balance (in shares) at Mar. 31, 2019	17,166,459
Balance at Dec. 31, 2018	$ 171,664	90,953,788		(57,909,874)	112,196	33,327,774
Balance (in shares) at Dec. 31, 2018	17,166,459
Options:
Comprehensive income (loss)						(172,345)
Net loss						(9,786,218)
Balance at Sep. 30, 2019	$ 175,655	93,376,856		(67,696,092)	(60,149)	25,796,270
Balance (in shares) at Sep. 30, 2019	17,565,534
Balance at Mar. 31, 2019	$ 171,664	91,301,295		(60,726,407)	314,382	31,060,934
Balance (in shares) at Mar. 31, 2019	17,166,459
Common Stock:
Restricted stock issued	$ 3,750	(3,750)		0	0	0
Restricted stock issued (in shares)	375,000
Restricted stock compensation, net	$ 0	307,774		0	0	307,774
Restricted stock compensation, net (in shares)	0
Options:
Exercised	$ 241	(241)		0	0	0
Exercised (in shares)	24,075
Stock option compensation	$ 0	69,097		0	0	69,097
Comprehensive income (loss)	0	0		0	(313,225)	(313,225)
Net loss	0	0		(3,186,680)	0	(3,186,680)
Balance at Jun. 30, 2019	$ 175,655	91,674,175		(63,913,087)	1,157	27,937,900
Balance (in shares) at Jun. 30, 2019	17,565,534
Common Stock:
Restricted stock compensation, net	$ 0	440,396		0	0	440,396
Restricted stock compensation, net (in shares)	0
Options:
Stock option compensation	$ 0	66,192		0	0	66,192
Warrant on term debt	0	1,196,093		0	0	1,196,093
Comprehensive income (loss)	0	0		0	(61,306)	(61,306)
Net loss	0	0		(3,783,005)	0	(3,783,005)
Balance at Sep. 30, 2019	$ 175,655	93,376,856		(67,696,092)	(60,149)	25,796,270
Balance (in shares) at Sep. 30, 2019	17,565,534
Balance at Dec. 31, 2019	$ 177,335	95,433,077	$ 0	(71,585,003)	9,844	24,035,253
Balance (in shares) at Dec. 31, 2019	17,733,617		0
Common Stock:
Restricted stock issued	$ 343	117,956	$ 0	0	0	118,299
Restricted stock issued (in shares)	34,249		0
Restricted stock compensation, net	$ (4,406)	(292,495)	$ 0	0	0	(296,901)
Restricted stock compensation, net (in shares)	(440,631)		0
Shares tendered for withholding taxes	$ 0	145,056	$ (145,056)	0	0	0
Shares tendered for withholding taxes (in shares)	0		(31,486)
Options:
Stock option compensation	$ 0	139,449	$ 0	0	0	139,449
Comprehensive income (loss)	0	0	0	0	(863,294)	(863,294)
Net loss	0	0	0	(4,999,549)	0	(4,999,549)
Balance at Mar. 31, 2020	$ 173,272	95,543,043	$ (145,056)	(76,584,552)	(853,450)	18,133,257
Balance (in shares) at Mar. 31, 2020	17,327,235		(31,486)
Balance at Dec. 31, 2019	$ 177,335	95,433,077	$ 0	(71,585,003)	9,844	24,035,253
Balance (in shares) at Dec. 31, 2019	17,733,617		0
Options:
Comprehensive income (loss)						(776,645)
Net loss						(18,382,144)
Balance at Sep. 30, 2020	$ 202,139	124,622,252	$ (150,919)	(89,967,147)	(766,803)	33,939,522
Balance (in shares) at Sep. 30, 2020	20,213,956		(33,290)
Balance at Mar. 31, 2020	$ 173,272	95,543,043	$ (145,056)	(76,584,552)	(853,450)	18,133,257
Balance (in shares) at Mar. 31, 2020	17,327,235		(31,486)
Common Stock:
Issuance of stock, net	$ 26,196	28,410,545	$ 0	0	0	28,436,741
Issuance of stock, net (in shares)	2,619,593		0
Restricted stock issued	$ 189	(189)	$ 0	0	0	0
Restricted stock issued (in shares)	18,858		0
Restricted stock compensation, net	$ (296)	262,405	$ 0	0	0	262,109
Restricted stock compensation, net (in shares)	(29,543)		0
Shares tendered for withholding taxes	$ 0	(192,161)	$ (5,863)	0	0	(198,024)
Shares tendered for withholding taxes (in shares)	0		(1,804)
Options:
Exercised	$ 55	(55)	$ 0	0	0	0
Exercised (in shares)	5,528		0
Stock option compensation	$ 0	122,115	$ 0	0	0	122,115
Warrants exercised	$ 2,532	(2,532)	$ 0	0	0	0
Warrants exercised (in shares)	253,161		0
Comprehensive income (loss)	$ 0	0	$ 0	0	(175,447)	(175,447)
Net loss	0	0	0	(7,843,797)	0	(7,843,797)
Balance at Jun. 30, 2020	$ 201,948	124,143,171	$ (150,919)	(84,428,349)	(1,028,897)	38,736,954
Balance (in shares) at Jun. 30, 2020	20,194,832		(33,290)
Common Stock:
Restricted stock issued	$ 191	105,561	$ 0	0	0	105,752
Restricted stock issued (in shares)	19,124		0
Restricted stock compensation, net	$ 0	275,985	$ 0	0	0	275,985
Restricted stock compensation, net (in shares)	0		0
Options:
Stock option compensation	$ 0	97,535	$ 0	0	0	97,535
Comprehensive income (loss)	0	0	0	0	262,094	262,094
Net loss	0	0	0	(5,538,798)	0	(5,538,798)
Balance at Sep. 30, 2020	$ 202,139	$ 124,622,252	$ (150,919)	$ (89,967,147)	$ (766,803)	$ 33,939,522
Balance (in shares) at Sep. 30, 2020	20,213,956		(33,290)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Cash received from customers and grants	$ 26,122,815	$ 29,423,872
Cash paid to suppliers and employees	(37,776,303)	(35,185,776)
Cash paid for operating leases	(797,482)	(474,150)
Cash paid for finance leases	(14,762)	(4,033)
Interest and taxes, net	(1,681,155)	(158,120)
Net cash used in operating activities	(14,146,887)	(6,398,207)
CASH FLOWS FROM INVESTING ACTIVITIES:
Patent application costs	(181,417)	(346,663)
Acquisition of and deposits on fixed assets	(3,000,763)	(2,568,244)
Acquisitions	0	145,760
Net cash used in investing activities	(3,182,180)	(2,769,147)
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of stock, net	28,436,741	0
Proceeds from issuance of long-term debt, net	0	18,850,000
Stimulus package loan	2,978,315	0
Payment of stimulus package loan	(2,978,315)	0
Payments of tax withholding on stock award	(348,944)	0
Payments on debt issuance costs	0	(186,313)
Payments on note payable	(180,249)	(136,232)
Payments on finance leases	(37,166)	(9,851)
Net cash provided by financing activities	27,870,382	18,517,604
Effect of exchange rate changes on cash	(125,214)	(6,909)
INCREASE IN CASH AND CASH EQUIVALENTS	10,416,101	9,343,341
Cash and cash equivalents - beginning of the period	18,271,352	12,524,551
Cash and cash equivalents - end of the period	28,687,453	21,867,892
RECONCILIATION OF NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:
Net loss	(18,382,144)	(9,786,218)
Adjustments:
Depreciation and amortization	2,057,275	1,666,675
Benefit from deferred tax liability	(301,000)	(402,639)
Provision of doubtful accounts	214,210	0
Non-cash inventory changes	2,530,444	0
Share based compensation	824,345	1,230,966
Changes in assets and liabilities:
Accounts receivable	138,827	1,995,986
Inventories	(5,295,899)	(558,122)
Prepaid expenses and other current assets	(314,460)	103,883
Deposits and other assets	80,873	(20,608)
Accounts payable and accrued liabilities	559,888	(442,725)
Deferred revenue	3,740,754	(185,405)
Net cash used in operating activities	(14,146,887)	(6,398,207)
Supplemental disclosures for non-cash investing and financing activities:
Deposits on manufacturing equipment transferred to fixed assets	$ 472,651	$ 430,000

SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2020

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES:

(a)

Basis of Presentation:

The accompanying unaudited condensed consolidated financial statements include the accounts of Chembio and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in Chembio’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the SEC.

The Company’s future working capital needs will depend on many factors, including the rate of its business and revenue growth, the timing of its continuing automation of U.S. manufacturing, and the timing of its investment in research and development as well as sales and marketing. If the Company is unable to increase its revenues and manage its expenses in accordance with its operating plan, it may need to reduce the level or slow the timing of the growth plans contemplated by its operating plan, which would likely curtail or delay the growth in its business contemplated by its operating plan and could impair or defer its ability to achieve profitability and generate cash flow, or to seek to raise additional funds through debt or equity financings, strategic relationships, or other arrangements.

All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of September 30, 2020. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.

(b)

Use of Estimates:

The preparation of the consolidated financial statements in conformity with GAAP requires management to make assumptions and estimates that affect the amounts reported in the accompanying unaudited condensed consolidated financial statements and these notes. Judgments and estimates of uncertainties are required in applying the Company’s accounting policies in certain areas. Generally, matters subject to estimation and judgment include accounts receivable realization, inventory, asset impairments, recognition of revenue including variable consideration and pursuant to milestones, useful lives of intangible and fixed assets, stock-based compensation, business combinations, and deferred tax asset valuation allowances. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from those estimates.

(c)

Fair Value of Financial Instruments:

The carrying values for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and other current liabilities approximate fair value due to the immediate or short-term maturity of these financial instruments. Included in cash and cash equivalents were $21.0 million and $16.0 million as of September 30, 2020 and December 31, 2019, respectively, of money market funds that are Level 1 fair value measurements under the hierarchy. The fair value of the Company’s total debt of $20.0 million (carrying value of $18.0 million) and $20.0 million (carrying value of $17.6 million) as of September 30, 2020 and December 31, 2019, respectively, is a Level 2 fair value measurement under the hierarchy, and the carrying value approximates fair value.

Fair value measurements of all financial assets and liabilities that are measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1:

Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2:

Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and,

Level 3:

Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

(d)

Cash and Cash Equivalents:

Cash and cash equivalents are defined as short-term, highly liquid investments with original maturities of three months or less, and include restricted cash of $2.3 million and $0 as of September 30, 2020 and December 31, 2019, respectively.

The Company is contractually obligated to maintain the restricted cash balance on deposit with a bank as security for the bank’s issuance of a guarantee on behalf of the Company for its performance under purchase orders from and related advance payments by a customer. The Company expects that the restriction will be released within the next twelve months.

(e)

Concentrations of Credit Risk:

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments and trade receivables. The Company places its temporary cash instruments with well-known financial institutions and, at times, may maintain balances in excess of the Federal Deposit Insurance Corporation insurance limit. The Company monitors the credit ratings of the financial institutions to mitigate this risk. Concentration of credit risk with respect to trade receivables is principally mitigated by the Company’s ability to obtain letters of credit from certain foreign customers and its diverse customer base, both in number of customers and geographic locations.

(f)

Fixed Assets:

Fixed assets are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, which range from three to seven years. Leasehold improvements are amortized over the useful life of the asset or the lease term, whichever is shorter. Deposits paid for fixed assets are capitalized and not depreciated until the related asset is placed in service.

(g)

Valuation of Long-Lived Assets and Intangible Assets:

Long-lived assets to be held and used are analyzed for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. The Company evaluates at each balance sheet date whether events and circumstances have occurred that indicate possible impairment. If there are indications of impairment, the Company uses future undiscounted cash flows of the related asset or asset grouping over the remaining life in measuring whether the assets are recoverable. In the event such cash flows are not expected to be sufficient to recover the recorded asset values, the assets are written down to their estimated fair value. No impairment of long-lived tangible and intangible assets was recorded for the nine months ended September 30, 2020 or 2019.

(h)

Revenue Recognition:

The Company recognizes revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. The Company recognizes revenue following the five-step model prescribed under Accounting Standards Update (“ASU”) 2014-09: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligation.

Product Revenue

Revenues from product sales are recognized and commissions are accrued when the customer obtains control of the Company’s product, which occurs at a point in time, typically upon tendering the product to the customer. The Company expenses incremental costs of obtaining a contract as and when incurred because the expected amortization period of the asset that it would have recognized is one year or less or the amount is immaterial. Freight and distribution activities on products are performed after the customer obtains control of the goods. The Company has made an accounting policy election to account for shipping and handling activities that occur either when or after goods are tendered to the customer as a fulfillment activity, and therefore recognizes freight and distribution expenses in cost of product sales. The Company excludes certain taxes from the transaction price (e.g., sales, value added and some excise taxes).

The Company’s contracts with customers often include promises to transfer products or services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require judgment. Typical products sold are diagnostic tests and typical services performed are R&D studies. Revenues from product sales are recognized at a point-in-time and revenues from R&D studies are recognized ratably over the period of the agreement, unless the related performance obligations indicate otherwise.

Judgment is required to determine the stand-alone selling price (“SSP”) for each distinct performance obligation. SSP is directly observable and the Company can use a range of amounts to estimate SSP, as it sells products and services separately, and can determine whether there is a discount to be allocated based on the relative SSP of the various products and services, for the various geographies.

The Company’s payment terms vary by the type and location of the Company’s customer and products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 60 days from date of shipment or satisfaction of the performance obligation.

Reserves for Discounts and Allowances

Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with the Company’s customers. The Company’s process for estimating reserves established for these variable consideration components does not differ materially from its historical practices.

Product revenue reserves, which are classified as a reduction in product revenues, are generally related to discounts and returns. Estimates of variable consideration and the determination of whether to include estimated amounts in the transaction price are based on all information (historical, current, and forecasted) that is reasonably available to the Company, taking into consideration the type of customer, the type of transaction, market events and trends, and the specific facts and circumstances of each arrangement. The transaction price, which includes variable consideration reflecting the impact of discounts, allowances and returns may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from the Company’s estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on revenue and earnings in the period of adjustment.

License and Royalty Revenue

The Company receives royalty revenue on sales by its licensee of products covered under patents that the Company owns. The Company does not have future performance obligations under this license arrangement. The Company records revenue based on estimates of the sales that occurred during the relevant period as a component of license and royalty revenue. The relevant period estimates of sales are based on interim data provided by the licensee and analysis of historical royalties that have been paid to the Company, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenue are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees.

R&D and Grant Revenue

All contracts with customers are evaluated under the five-step model described above. For certain contracts that represent grants where the funder does not meet the definition of a customer, the Company recognizes revenue when earned in accordance with Accounting Standards Codification (“ASC”) Topic 958. Such contracts are further described under Disaggregation of Revenue below. Grants are invoiced and revenue is recognized ratably as that is the depiction of the timing of the transfer of services. The R&D study, which encompasses various phases of product development processes: design feasibility & planning, product development and design optimization, design verification, design validation and process validation, and pivotal studies, is also recognized ratably.

In June 2018, the Financial Accounting Standards Board (the “FASB”) issued ASU 2018-08, Not-for-Profit Entities (Topic 958): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made. This ASU clarifies the guidance presented in ASC Topic 958, “Not-for-Profit Entities,” for evaluating whether a transaction is reciprocal (i.e., an exchange transaction) or nonreciprocal (i.e., a contribution) and for distinguishing between conditional and unconditional contributions. The ASU also clarified the guidance used by entities other than not-for-profits to identify and account for contributions made.

Disaggregation of Revenue

The following table disaggregates total revenues:

	For the Three Months Ended
	September 30, 2020						September 30, 2019
	Exchange Transactions		Non-Exchange Transactions		Total		Exchange Transactions		Non-Exchange Transactions		Total
Net product sales	$	8,406,457	$	-	$	8,406,457	$	8,510,629	$	-	$	8,510,629
R&D and grant revenue		1,444,724		209,776		1,654,500		880,458		91,522		971,980
License and royalty revenue		211,521		-		211,521		238,330		-		238,330
	$	10,062,702	$	209,776	$	10,272,478	$	9,629,417	$	91,522	$	9,720,939

	For the Nine Months Ended
	September 30, 2020						September 30, 2019
	Exchange Transactions		Non-Exchange Transactions		Total		Exchange Transactions		Non-Exchange Transactions		Total
Net product sales	$	17,914,623	$	-	$	17,914,623	$	23,381,906	$	-	$	23,381,906
R&D and grant revenue		3,546,385		209,776		3,756,161		2,272,454		1,255,579		3,528,033
License and royalty revenue		572,450		-		572,450		703,352		-		703,352
	$	22,033,458	$	209,776	$	22,243,234	$	26,357,712	$	1,255,579	$	27,613,291

Exchange transactions are recognized in accordance with ASC Topic 606, while non-exchange transactions are recognized in accordance with ASU 2018-08.

The following table disaggregates revenues by geographic location of the customer:

	For the Three Months Ended				For the Nine Months Ended
	September 30, 2020		September 30, 2019		September 30, 2020		September 30, 2019
Africa	$	1,874,518	$	1,250,063	$	3,310,603	$	6,009,103
Asia		168,052		505,379		650,659		746,025
Europe & Middle East		2,887,209		1,629,965		6,698,382		4,880,744
Latin America		4,618,560		4,296,903		7,515,523		9,981,874
United States		724,139		2,038,629		4,068,067		5,995,545
	$	10,272,478	$	9,720,939	$	22,243,234	$	27,613,291

Contract Liabilities

Deferred revenue relates to payments received in advance of performance under the contract. Deferred revenue is recognized as revenue as (or when) the Company performs under the contract. At September 30, 2020, the Company reported $3,865,754 in deferred revenue, of which $2.0 million is expected to be recognized during the three months ending December 31, 2020, and the remainder over the next 12 months.

(i)

Inventories:

Inventories consisted of the following at:

	September 30, 2020		December 31, 2019
Raw materials	$	6,633,884	$	2,901,319
Work in process		2,180,108		793,343
Finished goods		3,549,494		5,903,368
	$	12,363,486	$	9,598,030

(j)

Loss Per Share:

Basic loss per share is computed by dividing net loss attributable to holders of Chembio’s common stock (“common stock”) by the weighted-average number of shares of common stock outstanding for the period excluding unvested restricted stock. Diluted loss per share for the nine months ended September 30, 2020 and 2019 reflected the potential dilution from the exercise or conversion of other securities into common stock, if dilutive.

There were 634,851 and 650,093 restricted shares awards outstanding as of September 30, 2020 and 2019, respectively, that were not included in the calculation of diluted income per share for the three and nine months ended September 30, 2020 and 2019, because their effect would have been anti-dilutive. There were 950,997 and 672,472 weighted-average options outstanding as of September 30, 2020 and 2019, respectively, that were not included in the calculation of diluted income per share for the three and nine months ended September 30, 2020 and 2019, respectively, because their effect would have been anti-dilutive.

(k)

Research and Development:

R&D costs are expensed as incurred. Advance payments for goods and services that will be used in future R&D activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.

(l)

Equity Plans:

Effective June 3, 2008, Chembio’s stockholders voted to approve the 2008 Stock Incentive Plan (the “SIP”), with 625,000 shares of common stock available to be issued. At the Annual Stockholder Meeting on September 22, 2011, Chembio’s stockholders voted to approve an increase to the shares of common stock issuable under the SIP by 125,000 to 750,000. Under the terms of the SIP, which expired during 2018, the Board of Directors of Chembio (the “Board”) or its Compensation Committee had the discretion to select the persons to whom awards were to be granted. Awards could be stock options, restricted stock and/or restricted stock units (collectively, “Equity Award Units”). The awards became vested at such times and under such conditions as determined by the Board or its Compensation Committee. Cumulatively through September 30, 2020, there were 694,000 options expired, forfeited or exercised, and at September 30, 2020, 56,000 options were outstanding. No Equity Award Units are available to be issued under the SIP.

Effective June 19, 2014, Chembio’s stockholders voted to approve the 2014 Stock Incentive Plan (the “SIP14”), with 800,000 shares of common stock available to be issued. Under the terms of the SIP14, the Board or its Compensation Committee has the discretion to select the persons to whom awards are to be granted. Awards can be in the form of Equity Award Units. The awards vest at such times and under such conditions as determined by the Board or its Compensation Committee. Cumulatively through September 30, 2020, there were 479,375 Equity Award Units expired, forfeited or exercised. At September 30, 2020, 299,564 Equity Award Units were outstanding, and 0 Equity Award Units are available to be issued under the SIP14. Following the approval of the 2019 Plan (defined below), any Equity Award Units outstanding under the SIP14 remain subject to and be paid under the SIP14, and any shares subject to outstanding awards under the SIP14 that expire, terminate, or are surrendered or forfeited for any reason without issuance of shares automatically become available for issuance under the 2019 Plan.

Effective June 18, 2019, Chembio’s stockholders voted to approve the 2019 Omnibus Incentive Plan (the “2019 Plan”), with 2,400,000 shares of common stock available to be issued. In addition, shares of common stock underlying any outstanding award granted under the 2019 Plan that, following the effective date of the 2019 Plan, expire, or are terminated, surrendered or forfeited for any reason without issuance of such shares, are available for the grant of new awards under the 2019 Plan. Under the terms of the 2019 Plan, the Board or its Compensation Committee has the discretion to select the persons to whom awards are to be granted. Awards can be in the form of options, stock appreciation rights, restricted stock, restricted stock units, or other stock-based awards under the 2019 Plan (collectively, “2019 Equity Units”). The 2019 Equity Units become vested at such times and under such conditions as determined by the Board or its Compensation Committee. Cumulatively through September 30, 2020, 489,294 2019 Equity Units has been exercised or forfeited. At September 30, 2020, 1,230,286 2019 Equity Units were outstanding, and 1,311,096 2019 Equity Units were available to be awarded under the 2019 Plan.

(m)

Stock-Based Compensation:

The fair value of restricted stock and performance/restricted stock unit awards are determined on the date of grant or the date of issuance, as applicable. Stock-based compensation expense for stock options is calculated using the Black-Scholes valuation model. Stock based compensation is reduced for actual forfeitures in the period in which the forfeiture occurs and generally recognized on a straight-line basis over the service period of the grant. During the three and nine months ended September 30, 2020, 16,314 and 486,488 shares of restricted stock were forfeited, respectively. During the three and nine months ended September 30, 2020, 83,127 and 123,127 options were forfeited, respectively.

Stock-based compensation expense (net of recovery) recognized in the condensed consolidated statements of operations was classified as follows:

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2020		2019		2020			2019
Cost of product sales	$	-	$	2,691	$	6,300		$	8,479
Research and development expenses		126,333		56,251		281,070			172,346
Selling, general and administrative expenses		350,871		447,646		960,959			1,050,141
Severance and related costs		-		-		(423,984	)		-
	$	477,204	$	506,588	$	824,345		$	1,230,966

The weighted-average assumptions made in calculating the fair values of options were as follows:

	For the Nine Months Ended September 30, 2020
Expected term (in years)		6.3
Expected volatility		45.37	%
Expected dividend yield		0.00	%
Risk-free interest rate		1.33	%

The following table provides stock option activity for the nine months ended September 30, 2020:

Stock Options	Number of Shares	Weighted Average Exercise Price per Share		Weighted Average Remaining Contract Term	Aggregate Intrinsic Value
Outstanding at December 31, 2019	642,625	$	5.79	3 years	$	285,925

Granted	702,499		2.50			-
Exercised	(36,000)		6.30			95,976
Forfeited/expired/cancelled	(358,127)		2.44			-
Outstanding at September 30, 2020	950,997	$	4.09	5 years	$	-
Exercisable at September 30, 2020	205,583	$	7.59	3 years	$	-

The following table summarizes information about stock options outstanding at September 30, 2020:

	Stock Options Outstanding						Stock Options Exercisable
Range of Exercise Prices	Number of Shares	Average Remaining Contract Term (Years)	Weighted Average Exercise Price		Aggregate Intrinsic Value		Number of Shares	Weighted Average Exercise Price		Aggregate Intrinsic Value
$1 to $2.79999	636,364	6.46	$	2.36	$	-	-	$	-	$	-
$2.8 to $4.59999	-	-		-		-	-		-		-
$4.6 to $6.39999	59,883	3.42		5.56		-	30,000		5.51		-
$6.4 to $8.19999	207,875	3.30		7.31		-	147,458		7.28		-
$8.2 to $12	46,875	2.85		11.45		-	28,125		11.45		-
Total	950,997	5.40	$	4.09	$	-	205,583	$	7.59	$	-

As of September 30, 2020, there was $775,947 of net unrecognized compensation cost related to stock options that had not vested, which is expected to be recognized over a weighted-average period of approximately 2.35 years. The total fair value of shares vested during the nine months ended September 30, 2020 and 2019 was $172,145 and $295,412, respectively.

The following table summarizes information about restricted stock, restricted stock units and performance stock units outstanding as of September 30, 2020:

	Number of Shares & Units			Weighted- Average Grant Date Fair Value
Outstanding at December 31, 2019		545,986		$	7.47

Granted		642,081			2.68
Vested		(66,728	)		3.62
Forfeited/expired/cancelled		(486,488	)		6.43
Outstanding at September 30, 2020		634,851		$	3.43

As of September 30, 2020, there was $1,391,802 of net unrecognized compensation cost related to restricted stock and restricted stock units that had not vested, which is expected to be recognized over a weighted-average period of approximately 1.94 years.

(n)

Geographic Information and Economic Dependency

The Company produces only one group of similar products known collectively as “rapid medical tests,” and it operates in a single operating segment. Net product revenue by geographic area was as follows:

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2020		2019		2020		2019
Africa	$	1,874,518	$	1,250,063	$	3,310,603	$	6,009,103
Asia		168,052		505,379		650,659		746,025
Europe & Middle East		1,451,486		1,027,147		3,360,648		2,946,813
Latin America		4,618,560		4,296,904		7,515,523		9,981,874
United States		293,841		1,431,136		3,077,190		3,698,091
	$	8,406,457	$	8,510,629	$	17,914,623	$	23,381,906

Property, plant and equipment by geographic area was as follows:

	September 30, 2020		December 31, 2019
Asia	$	342,485	$	393,299
Europe & Middle East		161,173		165,029
Latin America		12,512		60,527
United States		7,516,942		5,314,714
	$	8,033,112	$	5,933,569

(o)

Accounts Payable and Accrued Liabilities:

Accounts payable and accrued liabilities consisted of:

	September 30, 2020		December 31, 2019
Accounts payable – suppliers	$	3,586,917	$	3,144,098
Accrued commissions and royalties		511,110		931,760
Accrued payroll		274,218		231,753
Accrued vacation		488,002		410,199
Accrued bonuses		575,479		215,000
Accrued severance		145,096		-
Accrued expenses – other		977,960		593,433
TOTAL	$	6,558,782	$	5,526,243

(p)

Goodwill, Long-Lived Assets and Intangible Assets:

The following table reflects changes in goodwill:

Beginning balance at December 31, 2019	$	5,872,690
Change in foreign currency exchange rate		(176,011	)
Balance at September 30, 2020	$	5,696,679

Intangible assets consisted of the following:

	September 30, 2020							December 31, 2019
	Weighted Average Remaining Useful Life	Cost		Accumulated Amortization		Net Book Value		Cost		Accumulated Amortization		Net Book Value
Intellectual property	5	$	1,586,043	$	420,818	$	1,165,225	$	1,418,681	$	299,232	$	1,119,449
Developed technology	5		2,009,962		487,637		1,522,325		1,922,682		266,550		1,656,132
Customer contracts/relationships	7		1,270,152		380,277		889,875		1,325,521		270,902		1,054,619
Trade names	7		111,568		40,498		71,070		114,946		30,794		84,152
		$	4,977,725	$	1,329,230	$	3,648,495	$	4,781,830	$	867,478	$	3,914,352

Intellectual property, developed technology, customer contracts/relationships and trade names are amortized over 10, 7, 10, and 11 years, respectively. Amortization expense for the nine months ended September 30, 2020 and 2019 was $149,222 and $378,691, respectively. Amortization expense, subject to changes in currency exchange rates, is expected to be approximately $598,000 per year from 2020 through 2024, and total $1,107,056 for all remaining years combined.

(q)

Taxes:

At the end of each interim reporting period, the Company estimates its effective tax rate expected to be applied for the full year. This estimate is used to determine the income tax provision or benefit on a year-to-date basis, and may change in subsequent interim periods. Accordingly, the Company’s effective tax rate for the three and nine months ended September 30, 2020 was 1.9% and 1.7%, compared to the effective tax rate of 0.5% and 3.9% for the three and nine months ended September 30, 2019. The Company’s effective tax rates for both periods were affected primarily by a full valuation allowance on domestic net deferred tax assets and a benefit from foreign net operating losses.

(r)

Allowance for Doubtful Accounts:

The Company records allowances for doubtful accounts for the estimated probable losses on uncollectible accounts receivable. The allowance is based upon the credit worthiness of the Company’s customers, the Company’s historical experience, the age of the receivable and current market and economic conditions. Receivables are written off against these allowances in the period they are determined to be uncollectible.

(s)

Foreign Currency Translation:

The functional currency of a foreign subsidiary is the local currency. Assets and liabilities of foreign subsidiaries that use a currency other than U.S. dollars as their functional currency are translated to U.S. dollars at end of period currency exchange rates. The consolidated statements of operations of foreign subsidiaries are translated to U.S. dollars at average period currency exchange rates. The effect of translation for foreign subsidiaries is generally reported in other comprehensive (loss) income. Foreign transaction gains and losses have been immaterial.

(t)

Acquisition Costs:

Acquisition costs include period expenses, primarily professional services, related to acquisition activities. For the nine months ended September 30, 2020 and 2019, the Company recognized $63,497 and $395,612 in acquisition costs related to its acquisition of Orangelife Comercio e Industria Ltda. ("Orangelife") and opTricon GmbH, respectively.

(u)

Recently Issued Accounting Standards:

Recently Adopted

ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”)

In June 2016, the FASB issued ASU 2016-13. ASU 2016-13 provides guidance on measurement of credit losses on financial instruments that changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, held-to-maturity debt securities and loans, and that requires entities to use a new, forward-looking “expected loss” model that is expected to generally result in the earlier recognition of allowances for losses. The guidance became effective for annual periods beginning after December 15, 2019, including interim periods within those years. The Company has evaluated the effects of this standard and determined that the adoption did not have a material impact on the Company’s consolidated financial statements.

ASU 2018-13, Fair Value Measurement - Disclosure Framework (Topic 820) (“ASU 2018-13”)

In August 2018, the FASB issued ASU 2018-13. ASU 2018-13 improves the disclosure requirements on fair value measurements. The updated guidance became effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company has evaluated the effects of this standard and determined that the adoption did not have a material impact on the Company’s consolidated financial statements.

ASU 2017-4, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-4”)

In January 2017, the FASB issued ASU 2017-4. ASU 2017-4 simplifies the subsequent measurement of goodwill and eliminates Step 2 from the goodwill impairment test. ASU 2017-4 is effective for annual and interim goodwill tests beginning after December 15, 2019. The Company has evaluated the effects of this standard and determined that the adoption did not have a material impact on the Company’s consolidated financial statements.

Not Yet Adopted

ASU 2020-06 - Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity

On August 5, 2020, the FASB issued ASU 2020-06, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. ASU 2020-06 simplifies the guidance in U.S. GAAP on the issuer’s accounting for convertible debt instruments, requires entities to provide expanded disclosures about “the terms and features of convertible instruments” and how the instruments have been reported in the entity’s financial statements. It also removes from ASC 815-40-25-10 certain conditions for equity classification and amends certain guidance in ASC 260 on the computation of EPS for convertible instruments and contracts on an entity’s own equity. An entity can use either a full or modified retrospective approach to adopt the ASU’s guidance. The ASU’s amendments are effective for smaller public business entities fiscal years beginning after December 15, 2023. The Company is currently evaluating the impact of adopting ASU 2020-06 on its consolidated financial statements.

ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting

In March 2020, the FASB issued ASC Topic 848. ASC Topic 848 provides relief for impacted areas as it relates to impending reference rate reform. ASC Topic 848 contains optional expedients and exceptions for applying GAAP to debt arrangements, contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective for upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance. The Company continues to assess all potential impacts of the standard and will disclose the nature and reason for any elections that the Company makes.

ASU 2019-12, Simplifications to Accounting for Income Taxes (“ASU 2019-12”)

In December 2019, the FASB issued ASU 2019-12. ASU 2019-12 removes certain exceptions for recognizing deferred taxes for investments, performing intra-period allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including deferred taxes for goodwill and allocating taxes for members of a consolidated group. ASU 2019-12 is effective for all entities for fiscal years beginning after December 15, 2020, and earlier adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2019-12 on its consolidated financial statements.

(w)

Severance, restructuring and other related costs:

During the nine months ended September 30, 2020, the Company recognized $0.7 million in net severance expenses related to the departure of Chembio’s former chief executive officer and the elimination of certain positions as part of its multi-faceted expense reduction program to reduce operating expenses. The Company undertook actions to adjust the size and composition of the organization, including by removing positions that were non-essential in light of its new business strategy, and to remove other expenses, all of which the Company expects will provide savings throughout, and after, 2020.

In light of market dynamics, the Company retrenched its Malaysian operations, including the termination of employment of its Malaysian workforce. The Company will maintain its Malaysian subsidiary and sustain the product registrations that were obtained throughout southeast Asia, with the benefit of having that entity and the WHO prequalification certified facility.

Based on these activities, the Company took restructuring actions totaling $0.4 million to realign and resize its production capacity and cost structure. All expenses have been paid as of September 30, 2020.

COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS

9 Months Ended

Sep. 30, 2020

COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS [Abstract]

COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS

NOTE 4 – COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS:

(a)

Concentrations:

The following table discloses product sales the Company had to customers that purchased in excess of 10% of the Company’s net product sales for the periods indicated:

	For the Three Months Ended										For the Nine Months Ended										Accounts Receivable as of
	September 30, 2020					September 30, 2019					September 30, 2020					September 30, 2019					September 30, 2020		Dec. 31, 2019
	Sales		% of Sales			Sales		% of Sales			Sales		% of Sales			Sales		% of Sales
Customer 1	$	4,226,040		50.3	%	$	3,966,142		46.6	%	$	6,523,416		36.4	%	$	10,012,644		42.8	%	$	1,622,866	$	941,962
Customer 2	$	1,071,513		12.7	%	$	-		-		$	-		-		$	-		-		$	-	$	-
Customer 3	$	963,671		11.5	%	$	-		-		$	-		-		$	-		-		$	17,510	$	-

Revenue includes product sales only, while accounts receivable reflects the total due from the customer, including freight.

The following table discloses purchases the Company made form vendors in excess of 10% of the Company’s net purchases for the periods indicated:

	For the Three Months Ended									For the Nine Months Ended									Accounts Payable as of
	September 30, 2020					September 30, 2019				September 30, 2020					September 30, 2019				September 30, 2020		Dec. 31, 2019
	Purchases		% of Purchases			Purchases		% of Purchases		Purchases		% of Purchases			Purchases		% of Purchases
Vendor 1	$	501,562		15.4	%	$	-		-	$	1,600,916		12.3	%	$	-		-	$	178,395	$	-

The Company currently buys materials that are purchased under intellectual property rights agreements and are important components in its products. Management believes that other suppliers could provide similar materials on comparable terms. A change in suppliers, however, could cause a delay in manufacturing, either from the logistic and regulatory implications of changing suppliers or from product attributable changes to new components, any of which could result in a possible loss of sales and adversely affect operating results.

(b)

Governmental Regulation:

All of the Company’s existing and proposed diagnostic products are regulated by the FDA U.S. Food and Drug Administration, the U.S. Department of Agriculture, certain U.S., state and local agencies, and/or comparable regulatory bodies in other countries. Most aspects of development, production, and marketing, including product testing, authorizations to market, labeling, promotion, manufacturing, and record keeping, are subject to regulatory review. After marketing approval has been granted, the Company must continue to comply with governmental regulations. Failure to comply with applicable requirements can lead to sanctions, including withdrawal of products from the market, recalls, refusal to authorize government contracts, product seizures, civil monetary penalties, injunctions, and criminal prosecution.

(c)

Employment Contracts:

As of September 30, 2020, the Company had multi-year contracts with two key employees that include salaries presently aggregating $765,000 per year. The contracts expire in December 2020 and December 2022. The following table is a schedule of future minimum salary commitments related to those contracts as of September 30, 2020:

2020	$	191,250
2021		765,000
2022		400,000

(d)

Pension Plan:

The Company has a 401(k) plan established for its employees whereby the Company matches 40% of the first 5% of salary (or up to 2% of salary) that an employee contributes to the plan. For the nine months ending September 30, 2020 and 2019, matching contribution expenses totaled $71,154, and $74,600, respectively.

(e)

Leases:

The Company leases facilities in New York, Germany, Malaysia, and Brazil, and certain equipment.

The Company’s facility leases generally include optional renewal periods. Upon entering into a new facility lease, the Company evaluates the leasehold improvements and regulatory requirements related to its operations in that location. To the extent that the initial lease term of the related facility lease is less than the useful life of the leasehold improvements and potential regulatory costs associated with moving the facility, the Company concludes that it is reasonably certain that a renewal option will be exercised, and thus that renewal period is included in the lease term and the related payments are reflected in the right-of-use asset and lease liability.

The Company’s facility leases generally include fixed rental payments with defined annual increases. While certain of the Company’s facility leases are gross leases, the majority of the Company’s facility leases are net leases in which the Company makes separate payments to the lessor based on the lessor’s property and casualty insurance costs, the property taxes assessed on the property, and a portion of the common area maintenance where applicable. The Company has elected the practical expedient not to separate lease and non-lease components for all of the Company’s facility leases. The Company has also elected the practical expedient for short term lease exception for all of its facility leases.

The components of lease expense were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Operating lease expense	$	405,989	$	425,757	$	1,258,797	$	1,108,016

Finance lease cost
Amortization of right-of-use assets	$	15,571	$	11,686	$	42,657	$	11,686
Interest on lease liabilities		5,395		4,033		14,762		4,033
Total finance lease expense	$	20,966	$	15,719	$	57,419	$	15,719

Supplemental cash flow information related to leases was as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	340,205	$	158,050	$	797,482	$	474,150
Operating cash flows for finance leases		5,395		4,033		14,762		4,033
Financing cash flows for finance leases		13,587		9,851		37,166		9,851
Right-of-use assets obtained in exchange for lease obligations:
Operating leases		-		-		-		6,697,896
Finance leases	$	5,486	$	-	$	73,600	$	222,036

Supplemental balance sheet information related to leases was as follows:

	September 30, 2020			September 30, 2019
Finance Leases
Finance lease right of use asset	$	315,153		$	233,722
Accumulated depreciation		(66,261	)		(11,686	)
Finance lease right of use asset, net	$	248,892		$	222,036

Weighted-Average Remaining Lease Term
Operating leases	9.1 years			9.9 years
Finance leases	4.0 years			4.8 years

Weighted-Average Discount Rate
Operating leases		8.60	%		8.51	%
Finance leases		8.18	%		7.00	%

During the three months ended March 31, 2019, the Company executed an operating sublease related to its former Holbrook, New York facility. The sublease ran conterminously with the base lease, for which the Company was primarily responsible until the end of the lease term in April 2020.

At the time of the initial assessment, the Company did not have an established incremental borrowing rate and the interest rates implicit in each of the leases were not readily determinable. Therefore, the Company used an interest rate based on the market place for the public debt. In September 2019, the Company entered into a credit agreement for a $20 million term loan as described on Note 5 - Long Term Debt.

Maturities of lease liabilities were as follows:

	September 30, 2020				September 30, 2019
	Operating Leases		Finance Leases		Operating Leases		Finance Leases
2019 and 2020	$	342,462	$	19,226	$	158,050	$	13,884
2021		1,209,787		76,904		813,443		55,536
2022		1,057,757		76,904		998,071		55,536
2023		1,026,272		76,904		1,026,044		55,536
2024		1,018,875		49,136		1,011,085		55,536
Thereafter		5,773,888		5,750		6,792,762		27,767
Total lease payments	$	10,429,041	$	304,824	$	10,799,455	$	263,795
Less: imputed interest		3,269,991		46,712		3,837,507		39,924
Total	$	7,159,050	$	258,112	$	6,961,948	$	223,871

(f)

Litigation:

Employee Litigation

John J. Sperzel III, our former chief executive officer, has asserted a right to exercise certain options to purchase, for an aggregate exercise price of $943,126, a total of 266,666 shares of common stock that were vested when he resigned on January 3, 2020. Under their terms, those options were exercisable for a period of thirty days after his service to our company ended. The compensation committee of the board, acting in its discretion in accordance with the terms of the underlying equity incentive plans, has determined that Sperzel’s attempt to exercise the options following the thirty day period was not valid. Chembio intends to vigorously defend against any claim by Mr. Sperzel that he continues to have a right to exercise any options.

Stockholder Litigation

Putative Stockholder Securities Class Action Litigation

As of November 3, 2020, four purported securities class action lawsuits had been filed by alleged stockholders of Chembio, and were pending, in the United States District Court for the Eastern District of New York:

•	Sergey Chernysh v. Chembio Diagnostics, Inc., Richard L. Eberly, and Gail S. Page, filed on June 18, 2020, which is referred to as the Chernysh case;

•	James Gowen v. Chembio Diagnostics, Inc., Richard L. Eberly, and Gail S. Page, filed on June 22, 2020, which is referred to as the Gowen case;

•	Anthony Bailey v. Chembio Diagnostics, Inc. Richard J. Eberly, Gail S. Page, and Neil A. Goldman, filed on July 3, 2020, which is referred to as the Bailey case; and

•

Special Situations Fund III QP, L.P., Special Situations Cayman Fund, L.P., and Special Situations Private Equity Fund, L.P. v. Chembio Diagnostics, Inc., Richard Eberly, Gail S. Page, Robert W. Baird & Co. Inc. and Dougherty & Company LLC, filed August 17, 2020, which is referred to as the Special Situations Funds case.

The plaintiffs in each of the cases allege violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 thereunder. The Special Situations Funds complaint also asserts claims under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 relating to Chembio’s May 2020 public offering. The claims asserted in the complaints are based on purportedly false and misleading statements and omissions concerning the performance of the DPP COVID-19 IgM/IgG System. The complaints collectively seek, among other things, an award of damages in an amount to be proven at trial, as well as an award of reasonable costs, including attorneys’ fees and expenses, expert fees, pre-judgement and post-judgment interest, and such other relief as the court deems just and proper. The Special Situations Funds complaint also asserts that members of the putative Section 11 class who continue to hold Chembio common stock have the right to rescind their purchases and recover the consideration paid. Chembio and the plaintiffs in the four cases have entered into court-approved stipulations relieving the defendants of the obligation to respond to the complaints in those cases pending the designation of a lead plaintiff pursuant to the Private Securities Litigation Reform Act of 1995. Two motions for appointment as lead plaintiff are currently pending for determination by the court; no date has been set for a hearing on any of those motions.

On July 1, 2020, an alleged stockholder of Chembio filed a purported class action lawsuit in the United States District Court for the Eastern District of New York captioned Ken Hayes v. Chembio Diagnostics, Inc., Richard L. Eberly, Gail S. Page, Katherine L. Davis, Mary Lake Polan, and John G. Potthoff, which is referred to as the Hayes case. The Hayes complaint purported to state claims for violations of Section 14(a) of the Exchange Act and Rule 14a‑9 thereunder, declaratory relief, and state law claims for breach of fiduciary duty for alleged misstatements of material information in the proxy statement disseminated in advance of Chembio’s Annual Meeting of Stockholders held on July 28, 2020. On July 8, 2020, Chembio filed an amended proxy statement correcting, among other things, the issues raised in the Hayes complaint. On July 23, 2020, (a) Chembio and the plaintiff entered into a stipulation to the dismissal of the Hayes action, with prejudice as to the claims of the named plaintiff subject to plaintiff’s reservation of the right to apply for an award of attorneys’ fees and expenses from Chembio in certain circumstances, and (b) the plaintiff filed a notice dismissing his claims, with prejudice, as to the individual defendants. On July 27, 2020, the court entered an order closing the Hayes case and providing that plaintiff would have until September 28, 2020 to move to reopen the case if the attorneys’ fee issue had not been resolved. Chembio subsequently resolved the attorneys’ fee issue amicably with the plaintiff.

Putative Stockholder Derivative Litigation

On September 11, 2020, a putative stockholder derivative action was filed purportedly on Chembio’s behalf in the United States District Court for the Eastern District of New York captioned Karen Wong, derivatively on behalf of Chembio Diagnostics, Inc., Plaintiff v. Richard L. Eberly, Gail S. Page, Neil A. Goldman, Javan Esfandiari, Katherine L. Davis, Mary Lake Polan, and John G. Potthoff, Defendants, and Chembio Diagnostics, Inc., Nominal Defendant, which is referred to as the Wong complaint. The Wong complaint purports to assert a claim for violation of Section 14(a) of the Exchange Act and Rule 14a-9 thereunder based on ostensibly false and misleading statements and omissions in the proxy statement disseminated in advance of Chembio’s 2020 Annual Meeting of Stockholders concerning Chembio’s rapid COVID-19 antibody tests. The Wong complaint also asserts claims against the individual defendants for purported breaches of fiduciary duties owed to Chembio and unjust enrichment.

The Wong complaint requests a declaration that the individual defendants have breached or aided and abetted the breach of their fiduciary duties to Chembio, an award of damages to Chembio, restitution, and an award of the plaintiff’s costs and disbursements in the action, including reasonable attorneys’ and experts’ fees, costs and expenses, and improvements to Chembio’s corporate governance and internal procedures. Pursuant to a stipulation by which the individual defendants in the Wong action agreed to waive service of process, the court ordered that the time for defendants to answer or otherwise respond to the complaint be extended to November 19, 2020. The parties subsequently entered into a stipulation for a stay of proceedings in the Wong action pending final disposition of motions to dismiss the pending putative class action litigation, subject to certain conditions. The court entered an order granting the requested stay on November 3, 2020.

SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2020

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

Basis of Presentation

(a)

Basis of Presentation:

Use of Estimates

(b)

Use of Estimates:

Fair Value of Financial Instruments

(c)

Fair Value of Financial Instruments:

Level 1:

Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2:

Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and,

Level 3:

Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Cash and Cash Equivalents

(d)

Cash and Cash Equivalents:

Concentrations of Credit Risk

(e)

Concentrations of Credit Risk:

Fixed Assets

(f)

Fixed Assets:

Valuation of Long-Lived Assets and Intangible Assets

(g)

Valuation of Long-Lived Assets and Intangible Assets:

Revenue Recognition

(h)

Revenue Recognition:

Product Revenue

Reserves for Discounts and Allowances

License and Royalty Revenue

R&D and Grant Revenue

Disaggregation of Revenue

The following table disaggregates total revenues:

	For the Three Months Ended
	September 30, 2020						September 30, 2019
	Exchange Transactions		Non-Exchange Transactions		Total		Exchange Transactions		Non-Exchange Transactions		Total
Net product sales	$	8,406,457	$	-	$	8,406,457	$	8,510,629	$	-	$	8,510,629
R&D and grant revenue		1,444,724		209,776		1,654,500		880,458		91,522		971,980
License and royalty revenue		211,521		-		211,521		238,330		-		238,330
	$	10,062,702	$	209,776	$	10,272,478	$	9,629,417	$	91,522	$	9,720,939

	For the Nine Months Ended
	September 30, 2020						September 30, 2019
	Exchange Transactions		Non-Exchange Transactions		Total		Exchange Transactions		Non-Exchange Transactions		Total
Net product sales	$	17,914,623	$	-	$	17,914,623	$	23,381,906	$	-	$	23,381,906
R&D and grant revenue		3,546,385		209,776		3,756,161		2,272,454		1,255,579		3,528,033
License and royalty revenue		572,450		-		572,450		703,352		-		703,352
	$	22,033,458	$	209,776	$	22,243,234	$	26,357,712	$	1,255,579	$	27,613,291

Exchange transactions are recognized in accordance with ASC Topic 606, while non-exchange transactions are recognized in accordance with ASU 2018-08.

The following table disaggregates revenues by geographic location of the customer:

	For the Three Months Ended				For the Nine Months Ended
	September 30, 2020		September 30, 2019		September 30, 2020		September 30, 2019
Africa	$	1,874,518	$	1,250,063	$	3,310,603	$	6,009,103
Asia		168,052		505,379		650,659		746,025
Europe & Middle East		2,887,209		1,629,965		6,698,382		4,880,744
Latin America		4,618,560		4,296,903		7,515,523		9,981,874
United States		724,139		2,038,629		4,068,067		5,995,545
	$	10,272,478	$	9,720,939	$	22,243,234	$	27,613,291

Contract Liabilities

Inventories

(i)

Inventories:

Inventories consisted of the following at:

	September 30, 2020		December 31, 2019
Raw materials	$	6,633,884	$	2,901,319
Work in process		2,180,108		793,343
Finished goods		3,549,494		5,903,368
	$	12,363,486	$	9,598,030

Loss Per Share

(j)

Loss Per Share:

Research and Development

(k)

Research and Development:

Equity Plans

(l)

Equity Plans:

Stock-Based Compensation

(m)

Stock-Based Compensation:

Stock-based compensation expense (net of recovery) recognized in the condensed consolidated statements of operations was classified as follows:

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2020		2019		2020			2019
Cost of product sales	$	-	$	2,691	$	6,300		$	8,479
Research and development expenses		126,333		56,251		281,070			172,346
Selling, general and administrative expenses		350,871		447,646		960,959			1,050,141
Severance and related costs		-		-		(423,984	)		-
	$	477,204	$	506,588	$	824,345		$	1,230,966

The weighted-average assumptions made in calculating the fair values of options were as follows:

	For the Nine Months Ended September 30, 2020
Expected term (in years)		6.3
Expected volatility		45.37	%
Expected dividend yield		0.00	%
Risk-free interest rate		1.33	%

The following table provides stock option activity for the nine months ended September 30, 2020:

Stock Options	Number of Shares	Weighted Average Exercise Price per Share		Weighted Average Remaining Contract Term	Aggregate Intrinsic Value
Outstanding at December 31, 2019	642,625	$	5.79	3 years	$	285,925

Granted	702,499		2.50			-
Exercised	(36,000)		6.30			95,976
Forfeited/expired/cancelled	(358,127)		2.44			-
Outstanding at September 30, 2020	950,997	$	4.09	5 years	$	-
Exercisable at September 30, 2020	205,583	$	7.59	3 years	$	-

The following table summarizes information about stock options outstanding at September 30, 2020:

	Stock Options Outstanding						Stock Options Exercisable
Range of Exercise Prices	Number of Shares	Average Remaining Contract Term (Years)	Weighted Average Exercise Price		Aggregate Intrinsic Value		Number of Shares	Weighted Average Exercise Price		Aggregate Intrinsic Value
$1 to $2.79999	636,364	6.46	$	2.36	$	-	-	$	-	$	-
$2.8 to $4.59999	-	-		-		-	-		-		-
$4.6 to $6.39999	59,883	3.42		5.56		-	30,000		5.51		-
$6.4 to $8.19999	207,875	3.30		7.31		-	147,458		7.28		-
$8.2 to $12	46,875	2.85		11.45		-	28,125		11.45		-
Total	950,997	5.40	$	4.09	$	-	205,583	$	7.59	$	-

The following table summarizes information about restricted stock, restricted stock units and performance stock units outstanding as of September 30, 2020:

	Number of Shares & Units			Weighted- Average Grant Date Fair Value
Outstanding at December 31, 2019		545,986		$	7.47

Granted		642,081			2.68
Vested		(66,728	)		3.62
Forfeited/expired/cancelled		(486,488	)		6.43
Outstanding at September 30, 2020		634,851		$	3.43

Geographic Information and Economic Dependency

(n)

Geographic Information and Economic Dependency

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2020		2019		2020		2019
Africa	$	1,874,518	$	1,250,063	$	3,310,603	$	6,009,103
Asia		168,052		505,379		650,659		746,025
Europe & Middle East		1,451,486		1,027,147		3,360,648		2,946,813
Latin America		4,618,560		4,296,904		7,515,523		9,981,874
United States		293,841		1,431,136		3,077,190		3,698,091
	$	8,406,457	$	8,510,629	$	17,914,623	$	23,381,906

Property, plant and equipment by geographic area was as follows:

	September 30, 2020		December 31, 2019
Asia	$	342,485	$	393,299
Europe & Middle East		161,173		165,029
Latin America		12,512		60,527
United States		7,516,942		5,314,714
	$	8,033,112	$	5,933,569

Accounts Payable and Accrued Liabilities

(o)

Accounts Payable and Accrued Liabilities:

Accounts payable and accrued liabilities consisted of:

	September 30, 2020		December 31, 2019
Accounts payable – suppliers	$	3,586,917	$	3,144,098
Accrued commissions and royalties		511,110		931,760
Accrued payroll		274,218		231,753
Accrued vacation		488,002		410,199
Accrued bonuses		575,479		215,000
Accrued severance		145,096		-
Accrued expenses – other		977,960		593,433
TOTAL	$	6,558,782	$	5,526,243

Goodwill, Long-Lived Assets and Intangible Assets

(p)

Goodwill, Long-Lived Assets and Intangible Assets:

The following table reflects changes in goodwill:

Beginning balance at December 31, 2019	$	5,872,690
Change in foreign currency exchange rate		(176,011	)
Balance at September 30, 2020	$	5,696,679

Intangible assets consisted of the following:

	September 30, 2020							December 31, 2019
	Weighted Average Remaining Useful Life	Cost		Accumulated Amortization		Net Book Value		Cost		Accumulated Amortization		Net Book Value
Intellectual property	5	$	1,586,043	$	420,818	$	1,165,225	$	1,418,681	$	299,232	$	1,119,449
Developed technology	5		2,009,962		487,637		1,522,325		1,922,682		266,550		1,656,132
Customer contracts/relationships	7		1,270,152		380,277		889,875		1,325,521		270,902		1,054,619
Trade names	7		111,568		40,498		71,070		114,946		30,794		84,152
		$	4,977,725	$	1,329,230	$	3,648,495	$	4,781,830	$	867,478	$	3,914,352

Taxes

(q)

Taxes:

Allowance for Doubtful Accounts

(r)

Allowance for Doubtful Accounts:

Foreign Currency Translation

(s)

Foreign Currency Translation:

Acquisition Costs

(t)

Acquisition Costs:

Recently Issued Accounting Standards

(u)

Recently Issued Accounting Standards:

Recently Adopted

ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”)

ASU 2018-13, Fair Value Measurement - Disclosure Framework (Topic 820) (“ASU 2018-13”)

ASU 2017-4, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-4”)

Not Yet Adopted

ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting

ASU 2019-12, Simplifications to Accounting for Income Taxes (“ASU 2019-12”)

(w)

Severance, restructuring and other related costs:

SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Sep. 30, 2020

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

Disaggregation of Revenue

The following table disaggregates total revenues:

	For the Three Months Ended
	September 30, 2020						September 30, 2019
	Exchange Transactions		Non-Exchange Transactions		Total		Exchange Transactions		Non-Exchange Transactions		Total
Net product sales	$	8,406,457	$	-	$	8,406,457	$	8,510,629	$	-	$	8,510,629
R&D and grant revenue		1,444,724		209,776		1,654,500		880,458		91,522		971,980
License and royalty revenue		211,521		-		211,521		238,330		-		238,330
	$	10,062,702	$	209,776	$	10,272,478	$	9,629,417	$	91,522	$	9,720,939

	For the Nine Months Ended
	September 30, 2020						September 30, 2019
	Exchange Transactions		Non-Exchange Transactions		Total		Exchange Transactions		Non-Exchange Transactions		Total
Net product sales	$	17,914,623	$	-	$	17,914,623	$	23,381,906	$	-	$	23,381,906
R&D and grant revenue		3,546,385		209,776		3,756,161		2,272,454		1,255,579		3,528,033
License and royalty revenue		572,450		-		572,450		703,352		-		703,352
	$	22,033,458	$	209,776	$	22,243,234	$	26,357,712	$	1,255,579	$	27,613,291

Exchange transactions are recognized in accordance with ASC Topic 606, while non-exchange transactions are recognized in accordance with ASU 2018-08.

The following table disaggregates revenues by geographic location of the customer:

	For the Three Months Ended				For the Nine Months Ended
	September 30, 2020		September 30, 2019		September 30, 2020		September 30, 2019
Africa	$	1,874,518	$	1,250,063	$	3,310,603	$	6,009,103
Asia		168,052		505,379		650,659		746,025
Europe & Middle East		2,887,209		1,629,965		6,698,382		4,880,744
Latin America		4,618,560		4,296,903		7,515,523		9,981,874
United States		724,139		2,038,629		4,068,067		5,995,545
	$	10,272,478	$	9,720,939	$	22,243,234	$	27,613,291

Inventories

Inventories consisted of the following at:

	September 30, 2020		December 31, 2019
Raw materials	$	6,633,884	$	2,901,319
Work in process		2,180,108		793,343
Finished goods		3,549,494		5,903,368
	$	12,363,486	$	9,598,030

Stock-Based Compensation Expense

Stock-based compensation expense (net of recovery) recognized in the condensed consolidated statements of operations was classified as follows:

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2020		2019		2020			2019
Cost of product sales	$	-	$	2,691	$	6,300		$	8,479
Research and development expenses		126,333		56,251		281,070			172,346
Selling, general and administrative expenses		350,871		447,646		960,959			1,050,141
Severance and related costs		-		-		(423,984	)		-
	$	477,204	$	506,588	$	824,345		$	1,230,966

Assumptions Made in Calculating Fair Values of Options

The weighted-average assumptions made in calculating the fair values of options were as follows:

	For the Nine Months Ended September 30, 2020
Expected term (in years)		6.3
Expected volatility		45.37	%
Expected dividend yield		0.00	%
Risk-free interest rate		1.33	%

Stock Option Activity

The following table provides stock option activity for the nine months ended September 30, 2020:

Stock Options	Number of Shares	Weighted Average Exercise Price per Share		Weighted Average Remaining Contract Term	Aggregate Intrinsic Value
Outstanding at December 31, 2019	642,625	$	5.79	3 years	$	285,925

Granted	702,499		2.50			-
Exercised	(36,000)		6.30			95,976
Forfeited/expired/cancelled	(358,127)		2.44			-
Outstanding at September 30, 2020	950,997	$	4.09	5 years	$	-
Exercisable at September 30, 2020	205,583	$	7.59	3 years	$	-

Stock Options Outstanding

The following table summarizes information about stock options outstanding at September 30, 2020:

	Stock Options Outstanding						Stock Options Exercisable
Range of Exercise Prices	Number of Shares	Average Remaining Contract Term (Years)	Weighted Average Exercise Price		Aggregate Intrinsic Value		Number of Shares	Weighted Average Exercise Price		Aggregate Intrinsic Value
$1 to $2.79999	636,364	6.46	$	2.36	$	-	-	$	-	$	-
$2.8 to $4.59999	-	-		-		-	-		-		-
$4.6 to $6.39999	59,883	3.42		5.56		-	30,000		5.51		-
$6.4 to $8.19999	207,875	3.30		7.31		-	147,458		7.28		-
$8.2 to $12	46,875	2.85		11.45		-	28,125		11.45		-
Total	950,997	5.40	$	4.09	$	-	205,583	$	7.59	$	-

Summary of Restricted Stock and Restricted Stock Units Outstanding

The following table summarizes information about restricted stock, restricted stock units and performance stock units outstanding as of September 30, 2020:

	Number of Shares & Units			Weighted- Average Grant Date Fair Value
Outstanding at December 31, 2019		545,986		$	7.47

Granted		642,081			2.68
Vested		(66,728	)		3.62
Forfeited/expired/cancelled		(486,488	)		6.43
Outstanding at September 30, 2020		634,851		$	3.43

Net Product Sales by Geographic Area

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2020		2019		2020		2019
Africa	$	1,874,518	$	1,250,063	$	3,310,603	$	6,009,103
Asia		168,052		505,379		650,659		746,025
Europe & Middle East		1,451,486		1,027,147		3,360,648		2,946,813
Latin America		4,618,560		4,296,904		7,515,523		9,981,874
United States		293,841		1,431,136		3,077,190		3,698,091
	$	8,406,457	$	8,510,629	$	17,914,623	$	23,381,906

Property, Plant and Equipment by Geographic Area

Property, plant and equipment by geographic area was as follows:

	September 30, 2020		December 31, 2019
Asia	$	342,485	$	393,299
Europe & Middle East		161,173		165,029
Latin America		12,512		60,527
United States		7,516,942		5,314,714
	$	8,033,112	$	5,933,569

Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consisted of:

	September 30, 2020		December 31, 2019
Accounts payable – suppliers	$	3,586,917	$	3,144,098
Accrued commissions and royalties		511,110		931,760
Accrued payroll		274,218		231,753
Accrued vacation		488,002		410,199
Accrued bonuses		575,479		215,000
Accrued severance		145,096		-
Accrued expenses – other		977,960		593,433
TOTAL	$	6,558,782	$	5,526,243

Changes in Goodwill

The following table reflects changes in goodwill:

Beginning balance at December 31, 2019	$	5,872,690
Change in foreign currency exchange rate		(176,011	)
Balance at September 30, 2020	$	5,696,679

Intangible Assets

Intangible assets consisted of the following:

	September 30, 2020							December 31, 2019
	Weighted Average Remaining Useful Life	Cost		Accumulated Amortization		Net Book Value		Cost		Accumulated Amortization		Net Book Value
Intellectual property	5	$	1,586,043	$	420,818	$	1,165,225	$	1,418,681	$	299,232	$	1,119,449
Developed technology	5		2,009,962		487,637		1,522,325		1,922,682		266,550		1,656,132
Customer contracts/relationships	7		1,270,152		380,277		889,875		1,325,521		270,902		1,054,619
Trade names	7		111,568		40,498		71,070		114,946		30,794		84,152
		$	4,977,725	$	1,329,230	$	3,648,495	$	4,781,830	$	867,478	$	3,914,352

SIGNIFICANT ACCOUNTING POLICIES, Part 1 (Details) - USD ($)	3 Months Ended			9 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Fair Value of Financial Instruments [Abstract]
Cash and cash equivalents		$ 28,687,453		$ 28,687,453		$ 18,271,352
Cash and Cash Equivalents [Abstract]
Restricted cash		2,300,000		2,300,000		0
Valuation of Long-Lived Assets and Intangible Assets [Abstract]
Goodwill impairment loss				0	$ 0
Disaggregation of Revenue [Abstract]
Total revenues		10,272,478	$ 9,720,939	22,243,234	27,613,291
Contract Liabilities [Abstract]
Deferred revenue		3,865,754		$ 3,865,754		125,000
Term over which revenue will be recognized				12 months
Inventories [Abstract]
Raw materials		6,633,884		$ 6,633,884		2,901,319
Work in process		2,180,108		2,180,108		793,343
Finished goods		3,549,494		3,549,494		5,903,368
Inventories		12,363,486		12,363,486		9,598,030
Forecast [Member]
Contract Liabilities [Abstract]
Recognition of deferred revenue	$ 2,000,000.0
Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues		10,062,702	9,629,417	22,033,458	26,357,712
Non-Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues		209,776	91,522	209,776	1,255,579
Africa [Member]
Disaggregation of Revenue [Abstract]
Total revenues		1,874,518	1,250,063	3,310,603	6,009,103
Asia [Member]
Disaggregation of Revenue [Abstract]
Total revenues		168,052	505,379	650,659	746,025
Europe & Middle East [Member]
Disaggregation of Revenue [Abstract]
Total revenues		2,887,209	1,629,965	6,698,382	4,880,744
Latin America [Member]
Disaggregation of Revenue [Abstract]
Total revenues		4,618,560	4,296,903	7,515,523	9,981,874
United States [Member]
Disaggregation of Revenue [Abstract]
Total revenues		724,139	2,038,629	4,068,067	5,995,545
Net Product Sales [Member]
Disaggregation of Revenue [Abstract]
Total revenues		8,406,457	8,510,629	17,914,623	23,381,906
Net Product Sales [Member] \| Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues		8,406,457	8,510,629	17,914,623	23,381,906
Net Product Sales [Member] \| Non-Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues		0	0	0	0
Net Product Sales [Member] \| Africa [Member]
Disaggregation of Revenue [Abstract]
Total revenues		1,874,518	1,250,063	3,310,603	6,009,103
Net Product Sales [Member] \| Asia [Member]
Disaggregation of Revenue [Abstract]
Total revenues		168,052	505,379	650,659	746,025
Net Product Sales [Member] \| Europe & Middle East [Member]
Disaggregation of Revenue [Abstract]
Total revenues		1,451,486	1,027,147	3,360,648	2,946,813
Net Product Sales [Member] \| Latin America [Member]
Disaggregation of Revenue [Abstract]
Total revenues		4,618,560	4,296,904	7,515,523	9,981,874
Net Product Sales [Member] \| United States [Member]
Disaggregation of Revenue [Abstract]
Total revenues		293,841	1,431,136	3,077,190	3,698,091
R&D and Grant Revenue [Member]
Disaggregation of Revenue [Abstract]
Total revenues		1,654,500	971,980	3,756,161	3,528,033
R&D and Grant Revenue [Member] \| Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues		1,444,724	880,458	3,546,385	2,272,454
R&D and Grant Revenue [Member] \| Non-Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues		209,776	91,522	209,776	1,255,579
License and Royalty Revenue [Member]
Disaggregation of Revenue [Abstract]
Total revenues		211,521	238,330	572,450	703,352
License and Royalty Revenue [Member] \| Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues		211,521	238,330	572,450	703,352
License and Royalty Revenue [Member] \| Non-Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues		0	$ 0	0	$ 0
Level 2 [Member]
Fair Value of Financial Instruments [Abstract]
Fair value of total debt		20,000,000.0		20,000,000.0		20,000,000.0
Carrying value		18,000,000.0		18,000,000.0		17,600,000
Money Market Funds [Member] \| Level 1 [Member]
Fair Value of Financial Instruments [Abstract]
Cash and cash equivalents		$ 21,000,000.0		$ 21,000,000.0		$ 16,000,000.0
Minimum [Member]
Fixed Assets [Abstract]
Estimated useful lives of fixed assets				3 years
Product Revenue [Abstract]
Revenue, payment terms				30 days
Maximum [Member]
Fixed Assets [Abstract]
Estimated useful lives of fixed assets				7 years
Product Revenue [Abstract]
Revenue, payment terms				60 days
Options [Member]
Loss Per Share [Abstract]
Shares excluded from computation of earnings per share (in shares)		950,997	950,997	672,472	672,472
Restricted Shares [Member]
Loss Per Share [Abstract]
Shares excluded from computation of earnings per share (in shares)		634,851	634,851	650,093	650,093

SIGNIFICANT ACCOUNTING POLICIES, Part 2 (Details) - USD ($)			3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 03, 2020	Jun. 03, 2008	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Sep. 30, 2020	Jun. 18, 2019	Jun. 19, 2014	Sep. 22, 2011
Stock options, additional disclosure [Abstract]
Granted, aggregate intrinsic value					$ 0
Forfeited/expired/cancelled, aggregate intrinsic value					0
Outstanding, aggregate intrinsic value, end of period			$ 0		0
Exercisable, aggregate intrinsic value, end of period			0		$ 0
Stock Options Outstanding [Abstract]
Number of Shares (in shares)								950,997
Average remaining contract term					5 years 4 months 24 days
Weighted average exercise price (in dollars per share)								$ 4.09
Aggregate intrinsic value			0		$ 0			$ 0
Stock Options Exercisable [Abstract]
Number of Shares (in shares)								205,583
Weighted average exercise price (in dollars per share)								$ 7.59
Aggregate intrinsic value			0		0			$ 0
Total fair value of stock options vested during period	$ 943,126
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]
Allocated share-based compensation expense			477,204	$ 506,588	824,345	$ 1,230,966
1 to 2.79999 [Member]
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period			0		0
Exercisable, aggregate intrinsic value, end of period			0		$ 0
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)					$ 1
Range of exercise prices, maximum (in dollars per share)					$ 2.79999
Stock Options Outstanding [Abstract]
Number of Shares (in shares)								636,364
Average remaining contract term					6 years 5 months 15 days
Weighted average exercise price (in dollars per share)								$ 2.36
Aggregate intrinsic value			0		$ 0			$ 0
Stock Options Exercisable [Abstract]
Number of Shares (in shares)								0
Weighted average exercise price (in dollars per share)								$ 0
Aggregate intrinsic value			0		0			$ 0
2.8 to 4.59999 [Member]
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period			0		0
Exercisable, aggregate intrinsic value, end of period			0		$ 0
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)					$ 2.8
Range of exercise prices, maximum (in dollars per share)					$ 4.59999
Stock Options Outstanding [Abstract]
Number of Shares (in shares)								0
Average remaining contract term					0 years
Weighted average exercise price (in dollars per share)								$ 0
Aggregate intrinsic value			0		$ 0			$ 0
Stock Options Exercisable [Abstract]
Number of Shares (in shares)								0
Weighted average exercise price (in dollars per share)								$ 0
Aggregate intrinsic value			0		0			$ 0
4.6 to 6.39999 [Member]
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period			0		0
Exercisable, aggregate intrinsic value, end of period			0		$ 0
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)					$ 4.6
Range of exercise prices, maximum (in dollars per share)					$ 6.39999
Stock Options Outstanding [Abstract]
Number of Shares (in shares)								59,883
Average remaining contract term					3 years 5 months 1 day
Weighted average exercise price (in dollars per share)								$ 5.56
Aggregate intrinsic value			0		$ 0			$ 0
Stock Options Exercisable [Abstract]
Number of Shares (in shares)								30,000
Weighted average exercise price (in dollars per share)								$ 5.51
Aggregate intrinsic value			0		0			$ 0
6.4 to 8.19999 [Member]
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period			0		0
Exercisable, aggregate intrinsic value, end of period			0		$ 0
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)					$ 6.4
Range of exercise prices, maximum (in dollars per share)					$ 8.19999
Stock Options Outstanding [Abstract]
Number of Shares (in shares)								207,875
Average remaining contract term					3 years 3 months 18 days
Weighted average exercise price (in dollars per share)								$ 7.31
Aggregate intrinsic value			0		$ 0			$ 0
Stock Options Exercisable [Abstract]
Number of Shares (in shares)								147,458
Weighted average exercise price (in dollars per share)								$ 7.28
Aggregate intrinsic value			0		0			$ 0
8.2 to 12 [Member]
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period			0		0
Exercisable, aggregate intrinsic value, end of period			0		$ 0
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)					$ 8.2
Range of exercise prices, maximum (in dollars per share)					$ 12
Stock Options Outstanding [Abstract]
Number of Shares (in shares)								46,875
Average remaining contract term					2 years 10 months 6 days
Weighted average exercise price (in dollars per share)								$ 11.45
Aggregate intrinsic value			0		$ 0			$ 0
Stock Options Exercisable [Abstract]
Number of Shares (in shares)								28,125
Weighted average exercise price (in dollars per share)								$ 11.45
Aggregate intrinsic value			$ 0		$ 0			$ 0
Stock Options [Member]
Share-based Arrangements with Employees and Nonemployees [Abstract]
Number of stock options expired, forfeited or exercised under the plan (in shares)					358,127
Number of stock options outstanding under the plan (in shares)			950,997		950,997		642,625	950,997
Assumptions made in calculating fair values of options [Abstract]
Expected term					6 years 3 months 18 days
Expected volatility					45.37%
Expected dividend yield					0.00%
Risk-free interest rate					1.33%
Stock options, number of shares [Roll forward]
Outstanding, beginning of period (in shares)					642,625
Granted (in shares)					702,499
Exercised (in shares)					(36,000)
Forfeited/expired/cancelled (in shares)					(358,127)
Outstanding, end of period (in shares)			950,997		950,997		642,625
Exercisable, end of period (in shares)			205,583		205,583
Stock options, outstanding, weighted average exercise price per share [Roll Forward]
Outstanding, beginning of period (in dollars per share)					$ 5.79
Granted (in dollars per share)					2.50
Exercised (in dollars per share)					6.30
Forfeited/expired/cancelled (in dollars per share)					2.44
Outstanding, end of period (in dollars per share)			$ 4.09		4.09		$ 5.79
Exercisable, end of period (in dollars per share)			$ 7.59		$ 7.59
Stock options, additional disclosure [Abstract]
Outstanding, weighted average remaining contract term					5 years		3 years
Exercisable, weighted average remaining contract term					3 years
Outstanding, aggregate intrinsic value, beginning of period					$ 285,925
Exercised, aggregate intrinsic value					95,976
Outstanding, aggregate intrinsic value, end of period			$ 0		0		$ 285,925
Exercisable, aggregate intrinsic value, end of period			0		0
Stock Options Outstanding [Abstract]
Aggregate intrinsic value			0		0		$ 285,925	$ 0
Stock Options Exercisable [Abstract]
Aggregate intrinsic value			$ 0		$ 0			0
Net unrecognized compensation cost								775,947
Weighted average period for recognition of net unrecognized compensation cost					2 years 4 months 6 days
Total fair value of stock options vested during period					$ 172,145	295,412
Weighted Average Grant Date Fair Value [Abstract]
Weighted average period for recognition of net unrecognized compensation cost					2 years 4 months 6 days
Restricted Stock and Restricted Stock Units [Member]
Stock Options Exercisable [Abstract]
Weighted average period for recognition of net unrecognized compensation cost					1 year 11 months 8 days
Number of Shares & Units [Abstract]
Outstanding, beginning of period (in shares)					545,986
Granted (in shares)					642,081
Vested (in shares)					(66,728)
Forfeited/expired/cancelled (in shares)					(486,488)
Outstanding, end of period (in shares)			634,851		634,851		545,986
Weighted Average Grant Date Fair Value [Abstract]
Outstanding, beginning of period (in dollars per share)					$ 7.47
Granted (in dollars per share)					2.68
Vested (in dollars per share)					3.62
Forfeited/expired/cancelled (in dollars per share)					6.43
Outstanding, end of period (in dollars per share)			$ 3.43		$ 3.43		$ 7.47
Net unrecognized compensation cost								$ 1,391,802
Weighted average period for recognition of net unrecognized compensation cost					1 year 11 months 8 days
2008 Stock Incentive Plan [Member] \| Stock Options [Member]
Share-based Arrangements with Employees and Nonemployees [Abstract]
Number of shares authorized under the plan (in shares)		625,000									750,000
Increase in number of shares authorized (in shares)		125,000
Number of stock options expired, forfeited or exercised under the plan (in shares)					694,000
Number of stock options outstanding under the plan (in shares)			56,000		56,000			56,000
Options or shares still available to be issued (in shares)								0
Stock options, number of shares [Roll forward]
Forfeited/expired/cancelled (in shares)					(694,000)
Outstanding, end of period (in shares)			56,000		56,000
2014 Stock Incentive Plan [Member] \| Stock Options [Member]
Share-based Arrangements with Employees and Nonemployees [Abstract]
Number of shares authorized under the plan (in shares)										800,000
Number of stock options expired, forfeited or exercised under the plan (in shares)					479,375
Number of stock options outstanding under the plan (in shares)			299,564		299,564			299,564
Options or shares still available to be issued (in shares)								0
Stock options, number of shares [Roll forward]
Forfeited/expired/cancelled (in shares)					(479,375)
Outstanding, end of period (in shares)			299,564		299,564
2019 Omnibus Incentive Plan [Member] \| Stock Options [Member]
Share-based Arrangements with Employees and Nonemployees [Abstract]
Number of shares authorized under the plan (in shares)									2,400,000
Number of stock options expired, forfeited or exercised under the plan (in shares)					489,294
Number of stock options outstanding under the plan (in shares)			1,230,286		1,230,286			1,230,286
Options or shares still available to be issued (in shares)								1,311,096
Number of stock options forfeited under the plan (in shares)			83,127		123,127
Stock options, number of shares [Roll forward]
Forfeited/expired/cancelled (in shares)					(489,294)
Outstanding, end of period (in shares)			1,230,286		1,230,286
2019 Omnibus Incentive Plan [Member] \| Restricted Shares [Member]
Share-based Arrangements with Employees and Nonemployees [Abstract]
Number of stock options expired, forfeited or exercised under the plan (in shares)			16,314		486,488
Stock options, number of shares [Roll forward]
Forfeited/expired/cancelled (in shares)			(16,314)		(486,488)
Cost of Product Sales [Member]
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]
Allocated share-based compensation expense			$ 0	2,691	$ 6,300	8,479
Research and Development Expenses [Member]
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]
Allocated share-based compensation expense			126,333	56,251	281,070	172,346
Selling, General and Administrative Expenses [Member]
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]
Allocated share-based compensation expense			350,871	447,646	960,959	1,050,141
Severance and Related Costs [Member]
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]
Allocated share-based compensation expense			$ 0	$ 0	$ (423,984)	$ 0

SIGNIFICANT ACCOUNTING POLICIES, Part 3 (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Geographic Areas, Revenues from External Customers [Abstract]
Sales	$ 10,272,478	$ 9,720,939	$ 22,243,234	$ 27,613,291
Geographic Areas, Property, Plant and Equipment [Abstract]
Property, plant and equipment	8,033,112		8,033,112		$ 5,933,569
Summary of accounts payable and accrued liabilities [Abstract]
Accounts payable - suppliers	3,586,917		3,586,917		3,144,098
Accrued commissions and royalties	511,110		511,110		931,760
Accrued payroll	274,218		274,218		231,753
Accrued vacation	488,002		488,002		410,199
Accrued bonuses	575,479		575,479		215,000
Accrued severance	145,096		145,096		0
Accrued expenses - other	977,960		977,960		593,433
Total	6,558,782		6,558,782		5,526,243
Net Product Sales [Member]
Geographic Areas, Revenues from External Customers [Abstract]
Sales	8,406,457	8,510,629	17,914,623	23,381,906
Africa [Member]
Geographic Areas, Revenues from External Customers [Abstract]
Sales	1,874,518	1,250,063	3,310,603	6,009,103
Africa [Member] \| Net Product Sales [Member]
Geographic Areas, Revenues from External Customers [Abstract]
Sales	1,874,518	1,250,063	3,310,603	6,009,103
Asia [Member]
Geographic Areas, Revenues from External Customers [Abstract]
Sales	168,052	505,379	650,659	746,025
Geographic Areas, Property, Plant and Equipment [Abstract]
Property, plant and equipment	342,485		342,485		393,299
Asia [Member] \| Net Product Sales [Member]
Geographic Areas, Revenues from External Customers [Abstract]
Sales	168,052	505,379	650,659	746,025
Europe & Middle East [Member]
Geographic Areas, Revenues from External Customers [Abstract]
Sales	2,887,209	1,629,965	6,698,382	4,880,744
Geographic Areas, Property, Plant and Equipment [Abstract]
Property, plant and equipment	161,173		161,173		165,029
Europe & Middle East [Member] \| Net Product Sales [Member]
Geographic Areas, Revenues from External Customers [Abstract]
Sales	1,451,486	1,027,147	3,360,648	2,946,813
Latin America [Member]
Geographic Areas, Revenues from External Customers [Abstract]
Sales	4,618,560	4,296,903	7,515,523	9,981,874
Geographic Areas, Property, Plant and Equipment [Abstract]
Property, plant and equipment	12,512		12,512		60,527
Latin America [Member] \| Net Product Sales [Member]
Geographic Areas, Revenues from External Customers [Abstract]
Sales	4,618,560	4,296,904	7,515,523	9,981,874
United States [Member]
Geographic Areas, Revenues from External Customers [Abstract]
Sales	724,139	2,038,629	4,068,067	5,995,545
Geographic Areas, Property, Plant and Equipment [Abstract]
Property, plant and equipment	7,516,942		7,516,942		$ 5,314,714
United States [Member] \| Net Product Sales [Member]
Geographic Areas, Revenues from External Customers [Abstract]
Sales	$ 293,841	$ 1,431,136	$ 3,077,190	$ 3,698,091

SIGNIFICANT ACCOUNTING POLICIES, Part 4 (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Goodwill [Abstract]
Goodwill impairment loss			$ 0	$ 0
Goodwill [Roll Forward]
Goodwill, Beginning balance			5,872,690
Changes in foreign currency exchange rate			(176,011)
Goodwill, Ending balance	$ 5,696,679		5,696,679
Intangible assets [Abstract]
Net Book Value	3,648,495		3,648,495		$ 3,914,352
Amortization Expense [Abstract]
Amortization expense 2020	598,000		598,000
Amortization expense 2021	598,000		598,000
Amortization expense 2022	598,000		598,000
Amortization expense 2023	598,000		598,000
Amortization expense 2024	598,000		598,000
Total	$ 1,107,056		$ 1,107,056
Taxes [Abstract]
Effective tax rate	1.90%	0.50%	1.70%	3.90%
Acquisition Costs [Abstract]
Acquisition costs	$ 0	$ 0	$ 63,497	$ 395,612
Severance, Restructuring and Other Related Costs [Abstract]
Severance expense			700,000
Restructuring costs			$ 400,000
Intellectual Property [Member]
Intangible assets [Abstract]
Weighted average remaining life of intangible assets			10 years
Developed Technology [Member]
Intangible assets [Abstract]
Weighted average remaining life of intangible assets			7 years
Customer Contracts / Relationships [Member]
Intangible assets [Abstract]
Weighted average remaining life of intangible assets			10 years
Trade Name [Member]
Intangible assets [Abstract]
Weighted average remaining life of intangible assets			11 years
CDM [Member]
Amortization Expense [Abstract]
Amortization expense	149,222	$ 378,691	$ 149,222	$ 378,691
OpTricon and CDM [Member]
Intangible assets [Abstract]
Cost	4,977,725		4,977,725		4,781,830
Accumulated Amortization	1,329,230		1,329,230		867,478
Net Book Value	3,648,495		$ 3,648,495		3,914,352
OpTricon and CDM [Member] \| Intellectual Property [Member]
Intangible assets [Abstract]
Weighted average remaining life of intangible assets			5 years
Cost	1,586,043		$ 1,586,043		1,418,681
Accumulated Amortization	420,818		420,818		299,232
Net Book Value	1,165,225		$ 1,165,225		1,119,449
OpTricon and CDM [Member] \| Developed Technology [Member]
Intangible assets [Abstract]
Weighted average remaining life of intangible assets			5 years
Cost	2,009,962		$ 2,009,962		1,922,682
Accumulated Amortization	487,637		487,637		266,550
Net Book Value	1,522,325		$ 1,522,325		1,656,132
OpTricon and CDM [Member] \| Customer Contracts / Relationships [Member]
Intangible assets [Abstract]
Weighted average remaining life of intangible assets			7 years
Cost	1,270,152		$ 1,270,152		1,325,521
Accumulated Amortization	380,277		380,277		270,902
Net Book Value	889,875		$ 889,875		1,054,619
OpTricon and CDM [Member] \| Trade Name [Member]
Intangible assets [Abstract]
Weighted average remaining life of intangible assets			7 years
Cost	111,568		$ 111,568		114,946
Accumulated Amortization	40,498		40,498		30,794
Net Book Value	$ 71,070		$ 71,070		$ 84,152

ACQUISITION (Details) - USD ($)		12 Months Ended
ACQUISITION (Details) - USD ($)	Nov. 25, 2019	Dec. 31, 2019	Sep. 30, 2020
Fair values of Assets Acquired and Liabilities Assumed [Abstract]
Goodwill		$ 5,872,690	$ 5,696,679
Orangelife [Member]
Business Combination, Consideration Transferred [Abstract]
Cash payment	$ 150,000
Shares issued (in shares)	153,707
Additional stock payment for acquisition based on approval of product registrations (in shares)	316,456
Fair value amount	$ 1,200,000
Fair values of Assets Acquired and Liabilities Assumed [Abstract]
Net current assets	320,293
Property, plant and equipment and other assets	226,035
Inventory	289,205
Goodwill	986,058
Deferred tax liability	(50,000)
Other intangible assets (estimated useful life) [Abstract]
Other intangible assets	200,000
Total consideration	1,971,591
Unaudited Pro Forma Operating Results [Abstract]
Total revenues		35,157,248
Net loss		$ (13,654,001)
Net loss per common share (in dollars per share)		$ (0.80)
Diluted net loss per common share (in dollars per share)		$ (0.80)
Orangelife [Member] \| Trade Name [Member]
Other intangible assets (estimated useful life) [Abstract]
Other intangible assets	$ 5,000
Weighted average useful life	6 months
Orangelife [Member] \| Customer Contracts / Relationships [Member]
Other intangible assets (estimated useful life) [Abstract]
Other intangible assets	$ 195,000
Weighted average useful life	5 years

COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS (Details)			3 Months Ended		9 Months Ended
	Nov. 03, 2020 Lawsuit	Jan. 03, 2020 USD ($) shares	Sep. 30, 2020 USD ($) KeyEmployee	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) KeyEmployee Applicants	Sep. 30, 2019 USD ($)	Dec. 31, 2019 USD ($)	Sep. 03, 2019 USD ($)
Concentrations [Abstract]
Sales			$ 10,272,478	$ 9,720,939	$ 22,243,234	$ 27,613,291
Accounts Receivable			$ 3,522,498		$ 3,522,498		$ 3,661,325
Employment Contracts [Abstract]
Number of key employees with whom Company has employment contracts \| KeyEmployee			2		2
Aggregate annual salaries of employment contracts					$ 765,000
Contract one, expiration date					Dec. 31, 2020
Contract two, expiration date					Dec. 31, 2022
Future minimum salary commitments [Abstract]
2020			$ 191,250		$ 191,250
2021			765,000		765,000
2022			400,000		$ 400,000
Pension Plan [Abstract]
Percentage of employer's matching contribution					40.00%
Expenses related to matching contribution					$ 71,154	74,600
Components of Lease Expense [Abstract]
Operating lease expense			405,989	425,757	1,258,797	1,108,016
Finance lease cost [Abstract]
Amortization of right-of-use assets			15,571	11,686	42,657	11,686
Interest on lease liabilities			5,395	4,033	14,762	4,033
Total finance lease expense			20,966	15,719	57,419	15,719
Cash paid for amounts included in the measurement of lease liabilities [Abstract]
Operating cash flows for operating leases			340,205	158,050	797,482	474,150
Operating cash flows for finance leases			5,395	4,033	14,762	4,033
Financing cash flows for finance leases			13,587	9,851	37,166	9,851
Right-of-use assets obtained in exchange for lease obligations [Abstract]
Operating leases			0	0	0	6,697,896
Finance leases			5,486	0	73,600	222,036
Finance Leases [Abstract]
Finance lease right of use asset			315,153	233,722	315,153	233,722
Accumulated depreciation			(66,261)	(11,686)	(66,261)	(11,686)
Finance lease right of use asset, net			$ 248,892	$ 222,036	$ 248,892	$ 222,036	210,350
Weighted Average Remaining Lease Term [Abstract]
Operating leases			9 years 1 month 6 days	9 years 10 months 24 days	9 years 1 month 6 days	9 years 10 months 24 days
Finance leases			4 years	4 years 9 months 18 days	4 years	4 years 9 months 18 days
Weighted Average Discount Rate [Abstract]
Operating leases			8.60%	8.51%	8.60%	8.51%
Finance leases			8.18%	7.00%	8.18%	7.00%
Maturities of Operating Lease Liabilities [Abstract]
2019 and 2020			$ 342,462	$ 158,050	$ 342,462	$ 158,050
2021			1,209,787	813,443	1,209,787	813,443
2022			1,057,757	998,071	1,057,757	998,071
2023			1,026,272	1,026,044	1,026,272	1,026,044
2024			1,018,875	1,011,085	1,018,875	1,011,085
Thereafter			5,773,888	6,792,762	5,773,888	6,792,762
Total lease payments			10,429,041	10,799,455	10,429,041	10,799,455
Less: imputed interest			3,269,991	3,837,507	3,269,991	3,837,507
Total			7,159,050	6,961,948	7,159,050	6,961,948
Maturities of Finance Lease Liabilities [Abstract]
2019 and 2020			19,226	13,884	19,226	13,884
2021			76,904	55,536	76,904	55,536
2022			76,904	55,536	76,904	55,536
2023			76,904	55,536	76,904	55,536
2024			49,136	55,536	49,136	55,536
Thereafter			5,750	27,767	5,750	27,767
Total lease payments			304,824	263,795	304,824	263,795
Less: imputed interest			46,712	39,924	46,712	39,924
Total finance lease liability			258,112	223,871	$ 258,112	223,871
Employee Litigation [Abstract]
Exercise price of stock options		$ 943,126
Vested shares exercisable (in shares) \| shares		266,666
Term to exercise stock options					30 days
Number of motions for appointment as lead plaintiff \| Applicants					2
Vendor 1 [Member]
Concentrations [Abstract]
Purchases			501,562	0	$ 1,600,916	0
Accounts Payable			178,395		178,395		0
Customer Concentration Risk [Member] \| Customer 1 [Member]
Concentrations [Abstract]
Accounts Receivable			1,622,866		1,622,866		941,962
Customer Concentration Risk [Member] \| Customer 2 [Member]
Concentrations [Abstract]
Accounts Receivable			0		0		0
Customer Concentration Risk [Member] \| Customer 3 [Member]
Concentrations [Abstract]
Accounts Receivable			17,510		$ 17,510		$ 0
Subsequent Event [Member]
Employee Litigation [Abstract]
Number of class action lawsuits \| Lawsuit	4
Maximum [Member]
Pension Plan [Abstract]
Employee contribution subject to employer matching contribution					5.00%
Employer matching contribution					2.00%
Senior Secured Term Loan Credit Facility [Member]
Leases [Abstract]
Debt instrument, face amount								$ 20,000,000
Sales [Member] \| Customer Concentration Risk [Member] \| Customer 1 [Member]
Concentrations [Abstract]
Sales			$ 4,226,040	$ 3,966,142	$ 6,523,416	$ 10,012,644
Concentration risk, percentage			50.30%	46.60%	36.40%	42.80%
Sales [Member] \| Customer Concentration Risk [Member] \| Customer 2 [Member]
Concentrations [Abstract]
Sales			$ 1,071,513	$ 0	$ 0	$ 0
Concentration risk, percentage			12.70%	0.00%	0.00%	0.00%
Sales [Member] \| Customer Concentration Risk [Member] \| Customer 3 [Member]
Concentrations [Abstract]
Sales			$ 963,671	$ 0	$ 0	$ 0
Concentration risk, percentage			11.50%	0.00%	0.00%	0.00%
Purchases [Member] \| Vendor 1 [Member]
Concentrations [Abstract]
Concentration risk, percentage			15.40%	0.00%	12.30%	0.00%

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
CURRENT ASSETS:
Accounts receivable, allowance for doubtful accounts	$ 276,210	$ 62,000
STOCKHOLDERS' EQUITY:
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	20,213,956	17,733,617
Treasury stock, shares (in shares)	33,290	0

DESCRIPTION OF BUSINESS	9 Months Ended
DESCRIPTION OF BUSINESS	Sep. 30, 2020
DESCRIPTION OF BUSINESS [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1 — DESCRIPTION OF BUSINESS: Chembio Diagnostics, Inc. (“Chembio”) and its subsidiaries (collectively with Chembio, the “Company”) develop and commercialize point-of-care rapid tests used for the detection and diagnosis of infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with the Company's extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers under the Company’s DPP, STAT PAK, SURE CHECK and STAT-VIEW registered trademarks or under the private labels of the Company’s marketing partners. The Company has been expanding its product portfolio based upon its proprietary DPP technology platform that provides high-quality, rapid diagnostic results in 15 to 20 minutes using a small drop of blood from the fingertip or alternative samples. Through advanced multiplexing, the DPP platform can detect up to eight, distinct test results from a single patient sample, which can deliver greater clinical value than other rapid tests. For certain applications, Chembio’s easy-to-use, highly portable, battery-operated DPP Micro Reader optical analyzer then reports accurate results in approximately 15 seconds, making it well-suited for decentralized testing where real-time results enable patients to be clinically assessed while they are still on-site. Objective results produced by the DPP Micro Reader can reduce the possibility of the types of human error that can be experienced in the visual interpretations required by many rapid tests. All DPP tests are developed and manufactured in the United States and are the subject of a range of domestic and global patents and patents pending. During the nine months ended September 30, 2020, the Company refocused its business strategy on the development and commercialization of the DPP COVID-19 IgM/IgG System, which consists of a new serological test for COVID-19 and a Micro Reader analyzer. In the nine months ended September 30, 2020, the Company developed, received regulatory approval in the US, Brazil and Europe, and commercialized the DPP COVID-19 IgM/IgG System, which provided numerical readings for both IgM and IgG levels of antibodies to the virus, and began developing its strategy for a portfolio of products both related to and expanding beyond COVID-19. On June 16, 2020, the U.S. FDA Food and Drug Administration (the "FDA") revoked the Company’s Emergency Use Authorization ("EUA") for the DPP COVID-19 System in the U.S., and the Company immediately began developing a revised version. The Company submitted an application for EUA to the FDA for its new rapid antibody test system, DPP SARS-CoV-2 IgM/IgG on September 8, 2020. On July 6, 2020, the Company received a $628,071 grant from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, Division of Research Innovation and Ventures ("BARDA") to assist the Company in developing a COVID-19 point-of-care antigen system using Chembio’s proprietary DPP technology and submitting an application for EUA to the FDA for the system. On October 15, 2020, Chembio submitted the EUA application for the DPP SARS-CoV-2 Antigen test system, which was designed to detect SARS-CoV-2 antigens in only 20 minutes. The DPP SARS-CoV-2 Antigen test system consists of a DPP SARS-CoV-2 Antigen test cartridge, a DPP Micro Reader optical analyzer and a minimally-invasive nasal swab. In addition to its DPP COVID-19 rapid test products, the Company has a broad portfolio of infectious disease products, which it expects to generate a diminished amount of revenue for the foreseeable future both due to the impact of the global COVID-19 pandemic and while it focuses on the development, manufacture, and commercialization of DPP COVID-19 products. Through Research & Development (“R&D”) Services, the Company is developing tests in collaboration with Takeda Pharmaceutical Company Limited. Large and growing markets have been established for these types of tests, initially in high prevalence regions where they are indispensable for large-scale prevention and treatment programs. More generally, the Company believes there is and will continue to be a growing demand for diagnostic products that can provide accurate, actionable diagnostic information in a rapid, cost-effective manner at the point of care. Through R&D Services, the Company develops tests for third parties using its DPP platform and, in limited cases, other platforms in projects that the Company believes have the potential to create value for the rest of its business. In addition, the Company routinely enters into arrangements with governmental and non-governmental organizations for the funding of certain R&D efforts.

LONG-TERM DEBT	9 Months Ended
LONG-TERM DEBT	Sep. 30, 2020
LONG-TERM DEBT [Abstract]
LONG-TERM DEBT	NOTE 5 – LONG-TERM DEBT: In September 2017, Chembio entered into an agreement with an equipment vendor to purchase automated assembly equipment for approximately $660,000. The terms call for payments of 30% down, 60% at time of factory acceptance testing and 10% after delivery. The vendor agreed to lend Chembio 15%, 40% and 10% of each originally scheduled payment, respectively. The Company paid interest at an annual rate of 12% until delivery. Beginning in September 2018, Chembio began making monthly payments of principal and interest of approximately $20,150, at an annual rate of 12% over a 24-month period. The note payable was fully repaid during the three months ended September 30, 2020. On September 3, 2019, Chembio entered into a Credit Agreement and Guaranty (the “Credit Agreement”) with Perceptive Credit Holdings II, LP (the “Lender”). The Credit Agreement provides for a $20,000,000 senior secured term loan credit facility, which was drawn in full on September 4, 2019. Under the terms of the Credit Agreement, Chembio may use the proceeds (i) for general working capital purposes and other permitted corporate purposes, (ii) to refinance certain of Chembio’s existing indebtedness and (iii) to pay fees, costs and expenses incurred in connection with the Credit Agreement, including the Lender’s closing cost amount of $550,000, which was netted from the proceeds, and a financing fee of $600,000 (3.0% of gross proceeds) payable to Chembio’s financial advisor for the financing. Principal outstanding under the Credit Agreement bears interest at a rate per annum equal to the sum of (a) the greater of the one-month London Interbank Offered Rate and 2.5% plus (b) 8.75%. At any time at which an event of default has occurred and is continuing, the interest rate will increase by 4.0%. Accrued interest is payable on a monthly basis. On June 30, 2020 the interest rate was 11.25%. No principal repayments are due under the Credit Agreement prior to September 30, 2022, unless Chembio elects to prepay principal or principal is accelerated pursuant to an event of default identified in the Credit Agreement. Principal installments in the amount of $300,000 are payable on the last day of each of the 11 months from September 2022 through July 2023, and all remaining principal is payable at maturity on September 3, 2023. Chembio may prepay outstanding principal from time to time, subject to payment of a premium on the prepaid principal amount equal to 10% through September 3, 2020, 8% from September 4, 2020 through September 3, 2021, and 4% from September 4, 2021 through September 3, 2022. No premium will be due with respect to any prepayment made on or after September 4, 2022. Chembio’s obligations under the Credit Agreement are secured by a first priority, perfected lien on substantially all of its property and assets, including its equity interests in subsidiaries. As of September 30, 2020, the loan balance, net of unamortized discounts and debt issuance costs, was $18.0 million, and Chembio was in compliance with its cash balance loan covenant, but not in compliance with its revenue loan covenant. Chembio obtained a written waivers from the Lender with respect to Chembio’s failure to meet the revenue loan covenant for the three months ended June 30, 2020 and three months ended September 30, 2020. Chembio's obligations under the Credit Agreement are secured by a first priority, perfected lien on substantially all of its property and assets, including its equity interests in subsidiaries.

DESCRIPTION OF BUSINESS (Details)	Jul. 06, 2020 USD ($)
DESCRIPTION OF BUSINESS [Abstract]
Grants received from Department of Health and Human Services	$ 628,071

LONG-TERM DEBT (Details) - Note Payable - Equipment Vendor [Member] - USD ($)	1 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2020
Debt Instruments [Abstract]
Debt instrument, face amount	$ 660,000
Percentage of first payment of the term	30.00%
Percentage of second payment of the term	60.00%
Percentage of prepayment after delivery	10.00%
Percentage of first payment of the term by the vendor	15.00%
Percentage of second payment of the term by the vendor	40.00%
Percentage of payment after delivery by the vendor	10.00%
Annual interest rate	12.00%
Periodic payment debt instrument, principal and interest	$ 20,150
Term of debt instrument		24 months

LONG-TERM DEBT, Credit Agreement (Details) - Senior Secured Term Loan Credit Facility [Member] - USD ($)		9 Months Ended
	Sep. 03, 2019	Sep. 30, 2020	Jun. 30, 2020
Credit Agreement [Abstract]
Debt instrument, face amount	$ 20,000,000
Lender's closing cost	550,000
Financing fee	$ 600,000
Percentage of gross proceeds considered as financing fee	3.00%
Interest rate	8.75%		11.25%
Increase in interest rate in event of default	4.00%
Principal installment payable	$ 300,000
Debt instrument maturity date		Sep. 03, 2023
Outstanding loan balance, net		$ 18,000,000.0
September 4, 2019 to September 3 ,2020 [Member]
Credit Agreement [Abstract]
Percentage of prepaid principal as premium	10.00%
September 4, 2020 to September 3 ,2021 [Member]
Credit Agreement [Abstract]
Percentage of prepaid principal as premium	8.00%
September 4, 2021 to September 3 ,2022 [Member]
Credit Agreement [Abstract]
Percentage of prepaid principal as premium	4.00%
LIBOR [Member]
Credit Agreement [Abstract]
Term of variable rate		1 month
Basis spread on variable rate	2.50%

WARRANTS (Details) $ / shares in Units, $ in Millions	9 Months Ended
WARRANTS (Details) $ / shares in Units, $ in Millions	Sep. 30, 2020 USD ($) $ / shares shares	Sep. 03, 2019 shares
WARRANTS [Abstract]
Warrant term	7 years
Warrants to purchase of common stock (in shares) \| shares		550,000
Estimated Fair Value of Warrant Assumptions [Abstract]
Stock price on issuance date (in dollars per share)	$ 5.40
Strike price (in dollars per share)	$ 5.22
Expected life	7 years
Fair value of warrants \| $	$ 1.4
Fair value of warrants (in dollars per share)	$ 2.49
Warrants outstanding \| $	$ 1.2
Shares received from exercise of warrant (in shares) \| shares	253,161
Risk-Free Interest Rate [Member]
Estimated Fair Value of Warrant Assumptions [Abstract]
Measurement input	0.0145
Volatility [Member]
Estimated Fair Value of Warrant Assumptions [Abstract]
Measurement input	0.4365